

## MSC functionalization for enhanced therapeutic applications

Kouroupis D<sup>1,2</sup>, Sanjurjo-Rodriguez C<sup>3,4</sup>, Jones E<sup>3</sup>, Correa D<sup>1,2\*</sup>

<sup>1</sup> Department of Orthopedics, UHealth Sports Medicine Institute, University of Miami, Miller School of Medicine, Miami, FL, USA

<sup>2</sup> Diabetes Research Institute & Cell Transplant Center, University of Miami, Miller School of Medicine, Miami, FL, USA

<sup>3</sup> Leeds Institute of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, UK

<sup>4</sup> Department of Biomedical Sciences, Medicine and Physiotherapy, University of A Coruña, CIBER-BBN - Institute of Biomedical Research of A Coruña (INIBIC), A Coruña, Spain

Dimitrios Kouroupis, PhD

1450 NW 10<sup>th</sup> Ave, Room 3012, Miami, FL, USA 33136.

Phone: +1 (305) 243-9285; Fax: +1 (305) 243-4404

Email: [dxk504@med.miami.edu](mailto:dxk504@med.miami.edu)

Clara Sanjurjo-Rodriguez, PhD

St James's University Hospital, Room 5.24 Clinical Sciences Building, Leeds LS9 7TF, UK

Phone: 44 (113) 206-5647; Fax: 44 (113) 343-8502

Email: [medcsanb@leeds.ac.uk](mailto:medcsanb@leeds.ac.uk)

Elena Jones, PhD

St James's University Hospital, Room 5.23 Clinical Sciences Building, Leeds LS9 7TF, UK

Phone: 44 (113) 206-5647; Fax: 44 (113) 343-8502

Email: [msjej@leeds.ac.uk](mailto:msjej@leeds.ac.uk)

Diego Correa, MD, MSc, PhD ***\*Corresponding Author***

1450 NW 10<sup>th</sup> Ave, Room 3014, Miami, FL, USA 33136.

Phone: 1 (305) 243-2228; Fax: 1 (305) 243-4404

Email: [dxk821@med.miami.edu](mailto:dxk821@med.miami.edu)

**Running title:** MSC subpopulations and priming methods

**Keywords:** mesenchymal stem cells, cellular phenotypes, MSC subpopulations, cell priming

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Tissue Engineering  
MSC functionalization for enhanced therapeutic applications (DOI: 10.1089/ten.TEB.2018.0118)

Downloaded by Univ Of Western Ontario from www.liebertpub.com at 09/08/18. For personal use only.

## ABSTRACT

To date, the therapeutic efficacy of human mesenchymal stem cells (hMSCs) has been investigated in various clinical trials with moderate or in some cases inconsistent results. The still elusive reproducibility relates in part with constitutive differences in the cell preparation, translated into variable “cell potencies”. Other factors include poor cell homing and survival, and age/disease-associated host tissue impairment. It is well accepted that within *in vivo* niches MSCs exist as heterogeneous cell populations with different stemness propensities and supportive functions. Phenotype-based MSC purification of homogeneous subsets can result in cell populations with distinct biological functions. In addition, preclinical studies have shown that MSC functionalization *in vitro*, via cell priming, can boost their immunomodulatory, trophic and reparative capacities *in vivo*. Therefore, in the present review we discuss how phenotype-based MSC purification and MSC priming technologies can contribute to an improved MSC-based product for safer and more effective therapeutic applications.

### IMPACT:

Culture expansion of MSC has detrimental effects on various cell characteristics and attributes (*e.g.*, phenotypic changes and senescence), which, in addition to inherent inter-donor variability negatively impact the standardization and reproducibility of their therapeutic potential. The identification of innate distinct functional MSC subpopulations, as well as the description of *ex vivo* protocols aimed at maintaining phenotypes and enhancing specific functions have the potential to overcome these limitations. The incorporation of those approaches into cell-based therapy would significantly impact the field, as more reproducible clinical outcomes may be achieved.

## INTRODUCTION

Safety and efficacy of human mesenchymal stem cells (MSCs)-based therapies are being investigated in a growing number of clinical trials for various disorders including musculoskeletal, cardiovascular, autoimmune, neurodegenerative and gastrointestinal (<http://clinicaltrials.gov>). Initial results from many of such studies reveal that these therapies show a significant degree of variability with cases of non-reproducible clinical data. The inconsistent evidence potentially relates to intrinsic differences in the cell-based products used, including lack of standardized features in the preparations reflected in “potency” discrepancies, as well as to factors related with the therapy itself (*e.g.*, cell homing to target tissues and subsequent survival), and the host receiving the therapy (*e.g.*, age and disease-associated conditions).

Active research is being conducted to help minimize the reported variability, ultimately aiming at increasing clinical reproducibility. Efforts include thorough characterization of cell preparations including the description of constitutive variations (*i.e.*, cell heterogeneity), and methods to stimulate MSCs with chemical and physical conditions to induce and/or to modulate specific attributes of the cells (*i.e.*, cell priming). In this review, we collect and discuss available evidence of such efforts, focusing on two main aspects: the identification of specific subsets/subpopulations of MSCs from different sources (heterogeneity), and the derivation of stimulatory protocols applied to the cells a priori to modulate cellular phenotypes and homing capacity (priming).

### 1. MSC SUBSETS/SUBPOPULATIONS

The fact that standard MSC cultures consist of functionally heterogeneous cell subsets is well recognized in the literature, however, the reasons for such heterogeneity are poorly understood. In our opinion, such heterogeneity arises from two different factors: firstly, from an inherent heterogeneity of culture-initiating MSCs, and second, from culture-induced accumulation of senescent cells, which in later passages become predominant and therefore significantly impact on cultures’ potency. As the latter phenomenon has been reviewed extensively (1, 2), this section will focus on tissue-

inherent MSC heterogeneity, which is closely linked to their local niches and tissue topography.

It is widely accepted that MSC populations within the different niches and tissues are highly heterogeneous; purification of homogeneous subsets with distinct biological functions is a challenge. However, isolated MSCs are generally analyzed for their clonogenic potential by the CFU-F assay and only limited information exists about markers that discriminate between developmentally, functionally and morphologically distinct MSC subsets (3). In here, we summarize recent studies aimed to identify different MSC subsets in the bone marrow (BM) as well as adipose and synovial tissues.

### 1.1 Bone marrow MSCs

#### Location markers: CD146 and CD271.

Bone marrow contains stem and progenitor cells for both hematopoietic and non-hematopoietic lineages. Bone marrow MSCs (referred also as multipotent stromal cells and skeletal stem cells - SSCs) reside in the postnatal BM cavities and give rise to bone, cartilage, marrow-fat and hematopoiesis-supportive stroma following a specific sequence of events during postnatal development (4-6). A pioneering work by Tormin et al has clearly demonstrated that human BM MSCs were present in two different regions within the BM cavities: in the perivascular niche, where they were characterized by CD146 marker expression, and in the bone-lining location, where MSC lacked this marker (7). Both, CD146<sup>+</sup> and CD146<sup>Neg</sup> MSC subpopulations were CD271<sup>+</sup> and had similar clonogenic capacities and gene expression profiles characterized by the simultaneous expression of multiple-lineage transcripts. Therefore, while CD271<sup>+</sup>CD146<sup>Neg</sup> cells are present in bone surfaces, CD271<sup>+</sup>CD146<sup>+</sup> MSCs constitute the *bona fide* perivascular component of the BM (Figure 1). Furthermore, adherent cultures derived from these two subpopulations had similar differentiation capacities *in vitro* and *in vivo*. In a more recent study Espagnolle et al have expanded BM MSCs at the clonal level and showed the presence of CD146<sup>high</sup> and CD146<sup>Neg/low</sup> clones (8). In agreement with Tormin et al study (7), they found no differences in the tri-lineage as well as hematopoietic support potentials between these two types of clones, however clonal cultures derived from the CD146<sup>high</sup> subset had slightly

slower growth rates and a more pronounced vascular smooth muscle phenotype, which was tested using functional cell contraction assay in a collagen gel. These findings supported Tormin et al study (7) in which BM CD146<sup>+</sup> cells were shown to have a topography of pericytes. The significance of CD146 expression on these perivascular MSCs remains to be investigated. In regards to CD146 expression on BM MSCs, it is interesting to mention that Maijenburg et al have also found CFU-Fs in the CD271<sup>Neg</sup>CD146<sup>+</sup> subset of fetal BM (9). CD146 expression was shown to be dependent on calcium (10) and oxygen levels (7) and can therefore reflect the niche environment in which this specific BM MSC subset resides. Less information is so far available with respect to CD146<sup>Neg</sup> BM MSCs. Because significant reduction of CD271<sup>+</sup>CD146<sup>+</sup> population was found in elderly adults, compared with children (9), it is possible that CD146<sup>Neg</sup> cells represent a subset of 'aged' BM MSCs, however, this is not consistent with Tormin et al data (7) that showed no differences in the clonogenicity between CD271<sup>+</sup>CD146<sup>+</sup> and CD271<sup>+</sup>CD146<sup>Neg</sup> subpopulations.

The perivascular localization concept of BM MSCs has been recently reinforced by Lin et al. pioneering study, showing that intra-arterially injected BM MSCs can serially engraft from the circulation into irradiated BM and proliferate *in vivo*, retaking the perivascular space around BM vessels and sinusoids (11). Recent reports (12, 13) expanded the notion of MSC subpopulations beyond the CD146 and CD271 discrimination reported in human BM, incorporating additional markers thus far identified in mouse studies. For instance, the perivascular BM MSCs can be further divided into two main categories according to the blood vessel they associate with: the periarteriolar MSCs (Nestin<sup>bright</sup>, NG2<sup>+</sup>,  $\alpha$ SMA<sup>+</sup>, CD271<sup>+</sup>, CD146<sup>+</sup>), and the perisinusoidal MSCs (Nestin<sup>dim</sup>, leptin receptor (LepR)<sup>+</sup>, CD271<sup>+</sup>, CD146<sup>+</sup>). These subpopulations have distinct functions as they support hematopoiesis and probably are related with local homeostatic responses. Along those lines, Mendez-Ferrer et al. showed that Nestin<sup>+</sup> MSCs contain all BM colony-forming-unit fibroblastic activity, are spatially associated with hematopoietic stem cells (HSCs) and highly express HSC maintenance and retention genes such as those encoding the cytokines chemokine (C-X-C motif) ligand 12 (CXCL12) and stem cell factor (SCF) (14, 15). These perivascular cells known as CXCL12-abundant reticular (CAR) cells express Nestin, LepR,

myxovirus resistance-1 (Mx-1), the transcription factor paired related homeobox-1 (Prx-1) that characterize cells of limb bud mesoderm, and transcription factor osterix (OSX or SP7) that regulates osteoblast maturation (13). Importantly, Sachetti et al. suggested that CD146<sup>+</sup> human MSCs may be the *in vitro* counterpart of CAR cells as they acquire the same phenotype in *in vivo* transplantation models reconstituting the hematopoietic environment (16). Therefore, except CD146<sup>+</sup> MSCs' ability to reconstitute bone and BM stroma after orthotopic and heterotopic transplantation models, they have an important role in HSC niche maintenance. To further support this notion, Corselli et al. showed that CD146<sup>+</sup>CD34<sup>Neg</sup>CD45<sup>Neg</sup> perivascular cells support the HSCs' stemness, through cell-to-cell contact and Notch signaling activation, and HSCs' ability to engraft to primary and secondary immunodeficient mice. In contrast, unfractionated and CD146<sup>Neg</sup> MSCs induce differentiation and inhibit *ex vivo* HSCs' maintenance (17).

In summary, the combined literature to date indicates that within human BM stroma, the CD146<sup>+</sup> subpopulation has a preferential perivascular topography and hematopoietic support function, whereas CD271 is expressed on both perivascular and bone lining MSCs; precise functions of these molecules on BM MSCs remain to be investigated.

#### **Other markers:**

In recent years, a number of novel markers to identify distinct MSC subsets within the CD271<sup>+</sup> fraction in human BM were proposed, including CD140b (18), MSCA-1 (19, 20), CD90 and CD106 (21), CD140a (22) and SUSD2 (20); however their expression *in situ* has not been performed therefore the precise tissue locations of these putative subsets remain unknown. Another surface marker of interest is CD56. Early studies have shown that CD56 molecule was highly-specific for bone-lining cells (23), in the same location of CD271<sup>+</sup>CD146<sup>Neg</sup> MSC subset in the Tormin et al study (7) (Figure 1); however CD56 has not as yet been used to isolate BM MSCs as a single marker or in combination with CD271. An interesting study from Buhning's laboratory (19) showed a distinct morphology and potential chondrogenic bias of the CD271<sup>+</sup>MSCA-1<sup>+</sup>CD56<sup>+</sup> BM MSC subset. These findings are awaiting an independent confirmation, but were confirmed in part by Cuthbert et al who found

MSCA-1 expression in the CD45<sup>Neg</sup>CD271<sup>+</sup> fraction of BM aspirates (24). Busser et al also found better chondrogenic potential of MSCA-1<sup>+</sup> selected MSCs than unselected ones and higher chondrogenic capacity from BM MSCs grown from the CD271<sup>+</sup> fraction (20). Contrary, Jezierska et al found better chondrogenesis of cultures expanded from CD271<sup>Neg</sup> rather than CD271<sup>+</sup> cells, after differentiation on gelated collagen microspheres (25).

CD271 marker is lost during culture expansion, therefore other markers were studied to discover MSC subpopulations present in both in fresh and early-passage expanded cells. When Qian et al tested CD44 as one of those markers, they found that CD44 was absent in freshly isolated BM MSC population because the cells that co-expressed CD271 and CD146 and displayed the clonogenic and multipotent functions were CD44<sup>Neg</sup> (26). However, CD44 marker was acquired by CD44<sup>Neg</sup> subset after *in vitro* expansion. This finding is unexpected because CD44 has always been considered as a “well-known” MSC surface marker in expanded-MSC studies (reviewed in Sousa et al (27)). In agreement with Qian et al study, Busser et al confirmed the higher clonogenicity of the CD44<sup>Neg</sup> fraction in the BM (20). These authors also found that CD44<sup>Neg</sup> fraction showed greater osteogenic potential than the total unselected population, but in contrast, no differences in chondrogenic potential were found between CD44<sup>Neg</sup> and CD44<sup>+</sup> cells (20). These authors also found greater osteogenic potential and clonogenic capacity in CD34<sup>+</sup> than CD34<sup>Neg</sup> cells or unselected BM MSC population. Again, CD34<sup>Neg</sup> and CD34<sup>+</sup> fractions did not show differences in the chondrogenic potential. As a result of different studies, CD34 had become another possible, but controversial marker for MSC subset selection from fresh BM aspirates (reviewed in Lin et al (28)).

#### **Functionally selected MSC subpopulations:**

Other approaches use cell division as functional parameter for identifying MSC subpopulations in early-passage MSCs (29), or clonal expansion methods (8, 30). After clonal expansion, Dickinson et al performed a comparative analysis between greatest and poorest chondrogenic clones and found that the expression of ROR2 positively correlated with chondrogenesis (30). *In situ* immunostaining corroborated the presence of ROR2<sup>+</sup> cells co-located with CD146<sup>+</sup> cells surrounding the blood vessels in the adult human BM. As

mentioned, Espagnolle et al (8) performed a selection of the expanded clones based on CD146 expression, for further analysis. Other markers were used to study heterogeneity in culture-expanded MSCs, such as ganglioside-based membrane microdomains (31).

Based on this information, it is fair to conclude that the existing literature supports the notion for at least two distinct topographies of MSCs in the BM (perivascular and bone-lining), however further work is needed to assess what effect these niches may have on MSC functionality assessed after their expansion and priming *in vitro*. It is possible that standard culture conditions lead to MSC's convergence to a common phenotype (32) therefore future investigations of BM MSC heterogeneity would benefit from a direct analysis of these cells immediately after purification.

### **Pre-clinical studies with MSC cultures derived from selected subpopulations**

Some selected BM subpopulations, mainly grown from CD271<sup>+</sup> cells, have been evaluated in pre-clinical studies. In one study, CD271<sup>+</sup> subpopulation of cultured BM MSCs when injected into infarcted murine heart, showed improved cardiac function (33). Another study reported improved repair of full thickness cartilage defects in rats using MSCs sorted for CD271<sup>+</sup> and expanded to form cell pellets that were placed in and covered with atelocollagen sponges (34). Also, CD271-MSCs promoted significantly greater lymphoid engraftment than did plastic adherence-MSCs when co-transplanted with HSCs in immunodeficient mice (35). Other preclinical studies with BM MSC subpopulations have been recently reviewed in Mo et al (36) and Lv et al (37).

## **1.2 Adipose tissue MSCs (ASCs)**

### **Location markers: CD146 and CD34**

Adipose tissue is a complex tissue of mesodermal origin that contains various cell types including adipose tissue MSCs, preadipocytes and mature adipocytes, fibroblasts, vascular smooth muscle cells, endothelial cells (ECs), monocytes/macrophages and lymphocytes (38). Obtaining MSC from adipose tissue, a waste product in several treatments, is popular due to the easy access to the tissue in large quantities. As for BM MSCs, two distinct MSC subsets have been discovered in human adipose tissue, but this



time they are CD146<sup>+</sup>CD34<sup>Neg</sup> pericytes and CD146<sup>Neg</sup>CD34<sup>+</sup> adventitial cells (both negative for CD45) (39, 40). *In situ* immunostaining of adipose tissue obtained from abdominoplasty showed CD146<sup>Neg</sup>CD34<sup>+</sup> cells localized in the outer vascular ring and CD146<sup>+</sup>/α-SMA<sup>+</sup> cells immediately adjacent to the vascular intima (39). In one study, a third population of CD146<sup>+</sup>CD34<sup>+</sup> was observed with a very low frequency by flow cytometry (approximately 0.5% of the nucleated stromal vascular fraction cells), presumably a transitional population between the pericytic and supra-adventitial perivascular ring cells. Further studies are necessary to confirm these markers *in situ*. The frequency of these subsets differs significantly depending on donor demographics and the way of tissue processing, but is still unclear how these variables affect the different subsets.

### Other markers

Bajek et al (41) studied the differences in early-passage ASC markers from tissues obtained either from mechanical or ultrasound-assisted liposuction, and they only found statistical differences in the expression of CD166. Other authors (20) did not find differences in CD166 expression that was low in both stromal cells from abdominoplasty and lipoaspirate, although they observed that CD271<sup>+</sup> selected ASCs were highly proliferative and clonogenic only in lipoaspirate samples, being the contrary for abdominoplasty ones (CD271<sup>Neg</sup> fraction). Interestingly, CD271 marker was not mentioned in many characterization studies (42, 43). Importantly, Baer et al. (42) performed the first comprehensive phenotypic characterization of cultured adipose-derived stromal cells (ASCs) isolated from lipoaspirates. They found that ASCs expressed the characteristic MSC's markers CD29, CD44, CD73, CD90, CD105 and CD166 but there was high donor variability for 49 of the 242 markers tested, including CD34 and CD200. These findings can be explained by the fact that CD271, as well as other molecules present on native adipose MSC subsets can be lost in culture.

The difficulty in analyzing adipose tissue MSC literature is that adipose tissue is highly vascular and it is widely accepted that following digestion and removal of red cells, the remaining cells consist of leukocytes, stromal cells and ECs. Subsequent dissection of stromal cells and ECs is complicated by the fact that many 'MSC' specific molecules - CD73,

CD105, CD146 and some authors even consider CD90 - are also expressed on ECs (reviewed in Lin et al. (44)). Conversely, a typical endothelial progenitor molecule CD34 can be expressed on adipose MSCs (reviewed in Sidney et al. (45)), as stated above. So, these markers are not very useful alone for segregating MSCs from ECs however CD31<sup>Neg</sup>CD45<sup>Neg</sup> combination can discriminate leukocytes and ECs from adipose MSCs as published by the ISCT together with the International Federation for Adipose Therapeutics and Science (IFATS) (43). These authors published a guidance for minimal criteria for stromal cells from adipose tissue, as previously performed for general MSC. This guide differentiates between freshly-isolated stromal cells as “uncultured stromal vascular fraction” (SVF), identified mainly as CD45<sup>Neg</sup>CD235a<sup>Neg</sup>CD31<sup>Neg</sup>CD34<sup>+</sup> subset, and cultured stromal cells (ASCs), characterized as CD45<sup>Neg</sup>CD31<sup>Neg</sup>CD36<sup>+</sup>CD106<sup>Neg</sup> cells. Overall, the literature agrees that CD34<sup>+</sup> may be present on a subset of native adipose MSCs, but it is lost in prolonged culture expansion (46) and is not useful as a sole marker as CD34 is also expressed on ECs and other cell types (44, 45). However, CD34 was considered a good marker for MSC enrichment from SVF fraction by Busser et al (20) as CD34<sup>+</sup> ASCs were significantly more clonogenic and proliferative than parental cells. Furthermore, Bourin et al (43) observed that both SVF and ASCs express CD73, CD90 and CD105, although CD44 expression is only present in the cultured ASCs, which seems to be similar to CD44 pattern of expression on BM MSCs (26). Also, Bourin et al (43) suggested additional positive markers with variable expression, as CD146. Despite this, one study did not found expression of CD106 and CD146 markers in culture expanded-ASCs, but passage number at which cells were analyzed was not specified (47).

### Functionally selected MSC subpopulations

Different from BM, Busser et al (20) found that adipose MSCs did not express SUSD2, MSCA-1/TNAP and CD44 *in situ*, but this data that needs to be confirmed. Hardy et al (48), performed enrichment of CD146<sup>+</sup>CD34<sup>Neg</sup> and CD146<sup>Neg</sup>CD34<sup>+</sup> subsets from adipose MSC tissue collected by lipoaspiration, focusing on the aldehyde dehydrogenase (ALDH) staining intensity. After culturing single-cell sorted cells, transcriptional profile analysis was done and ALDH<sup>bright</sup> cells were considered as the most primitive cell population within both

subpopulations. Considering that this study was only performed using one sample, further confirmation is necessary.

In general, differently from BM MSCs, most of the studies using adipose MSCs don't study chondrogenesis. There also exists controversy about MSC variability due to age, body mass index, niche location and the way of tissue processing that complicates data interpretation but may lead in the future to discovery of many more subtypes of adipose MSCs. For example, the possibility of finding different MSCs subpopulations that can support different types of blood vessels. So probably, different vascularity seen in lipoaspirates and solid fat tissues can be the reason for different types of MSCs found but more work is needed to study the relationship between these blood vessels and MSCs. Despite of all these unanswered questions, surprisingly, SVF are being used for clinical treatment of human cartilage damage (reviewed in Pak et al (49)).

#### **Pre-clinical studies with MSC cultures derived from selected subpopulations:**

In pre-clinical studies using AT MSCs, mainly CD34<sup>+</sup>, CD105<sup>+</sup> and CD90<sup>+</sup> subpopulations were tested. One study compared CD90<sup>+</sup> and CD105<sup>+</sup> subpopulations of cultured MSCs seeded on hydroxyapatite (HA)-coated polylactic-co-glycolic acid (PLGA) scaffolds in calvarial defects in mice and showed better bone formation from CD90<sup>+</sup> subpopulation (50). In calvarial defects in mice, cultures grown from CD105<sup>low</sup> sorted cells and seeded on HA-PLGA scaffolds formed more robust bone than cultures grown from CD105<sup>high</sup> cells (51). Other preclinical studies with selected AT MSCs have been reviewed in Johal et al (52).

### **1.3 Synovial MSCs**

#### **Location markers**

The synovial membrane is a specialized tissue of mesodermal origin lining the spaces of diarthrodial joints, bursae and tendon sheaths. It contains two compartments, the intima inner continuous cell compartment composed of fibroblast-like synoviocytes, and the subintima compartment composed of few macrophages and lymphocytes, fat cells, and blood vessels (53). Interestingly, the origin of synovium-derived MSCs in the

synovial lining is still under investigation and can be related to infiltrated MSCs through vasculature or BM originated MSCs that connects to intra-articular space. Recently, two studies showed that single or double positive Prg4-lineage and Gdf5-lineage cells, both present in the synovium, contribute to repair of articular cartilage injuries in mice (54, 55). Despite the hypothesis of the involvement of synovium-derived MSCs in cartilage repair is beginning to gain strength (56), *in vivo* and *in vitro* studies about synovium MSCs are scarce compared with MSCs from other tissues such as adipose or BM. A comprehensive review of clinical studies utilizing intra-articular MSC therapy showed that only 7% of the studies reviewed used MSCs from synovial membrane (57). The same applies to *in vitro* studies, in which much fewer investigations were focused on synovial MSCs, mainly culture-expanded cells, compared to BM MSCs.

In a pioneering study, Karystinou et al (58) reported for the first time the presence of cell subsets with distinct characteristics within the synovial membrane. They performed cell cloning by limiting dilution and found variations in MSC proliferation and potency: all clonal populations were chondro-osteogenic and only 33% of them were also adipogenic, unlike the parental MSC population that was tripotential. Phenotype evaluation of tripotential extensively-expanded clones by flow cytometry showed positivity for markers such as CD13, CD73, CD81, CD90, CD105, CD166 and SSEA-4. However, these authors did perform neither enrichment of these tripotential MSCs nor phenotypic analysis of bi-potential clones. Besides, in this study not all of the clones isolated were culture-expandable. Taking this into account and also the fact that markers as CD271 are undetectable after extensive expansion (59-61), recent studies are being focused in early-passage expanded (passages 0 to 1) or freshly-isolated MSCs.

Hermida-Gomez et al (62) performed the first MSC topographic analysis of the synovial tissue, showing CD271<sup>+</sup> cells present in its intima lining in healthy donors but also along vascular subintima in osteoarthritic patients, a likely route for the mobilization of the MSCs to reach the cartilage damage. However, other authors associated the increase of CD271<sup>+</sup> MSCs in synovial membrane of arthritic patients with pro-inflammatory function (61). Hermida-Gomez et al (62) found that CD271<sup>+</sup> cells present in synovium had a high co-expression of CD44 and CD90 but low levels of CD105. The low positivity of CD105 in

addition to CD166, in freshly isolated synovial MSCs was confirmed by Jones et al (63) using flow cytometry. In spite of the low percentage of CD105<sup>+</sup> MSCs present in synovial membrane, early-passage-CD105-selected cultures had good chondrogenic capacity after spheroid formation (64), but this study did not compare results with CD105<sup>Neg</sup> or total MSCs because these cells were not capable to form spheroids.

More recently, Mizuno et al (65) proposed different phenotypes of MSC in the osteoarthritic synovium based on their topography: CD55<sup>+</sup> MSCs in the surface region, CD271<sup>-</sup>CD55<sup>-</sup> in the stromal region and CD271<sup>+</sup> in the perivascular region. However, these results need to be confirmed in healthy synovium.

### Other markers

Another marker used for subsets analysis and enrichment from early-passage culture-expanded synovial MSCs was CD73, which enriched for cells with higher chondrogenic potency than CD106 marker (66). Also, CD44 expression was correlated with chondrogenic capacity (63), however no CD44 enrichment was performed in this study. Combinations of markers, such as CD73 and CD39 were later used for enrichment of synovial MSCs from early and late passages synovial cultures, and CD73<sup>+</sup>CD39<sup>+</sup> subset was found to be more chondrogenic and osteogenic than CD73<sup>+</sup>CD39<sup>Neg</sup> subset (67). However, when these authors compared culture-expanded and freshly isolated synovial cells they found no differences in clonogenicity and chondro-osteogenic potential between CD73<sup>+</sup>CD39<sup>+</sup> and CD73<sup>+</sup>CD39<sup>Neg</sup> subsets confirming the necessity of performing this type of analysis using freshly isolated synovial cells. Furthermore, as commented above, markers such as CD271 are known to be downregulated following MSC culture-expansion; similarly CD34 marker was detected in directly isolated synovial cells, but declining following MSC passaging (60).

To summarize, more work in this area is required to provide a convincing argument for the use of specific markers for the isolation of any functionally relevant subsets of synovial MSCs. To the best of our knowledge, no pre-selection of synovial MSC populations was performed in pre-clinical studies.

Altogether, while MSC are being largely used in clinical trials as bulk-expanded heterogeneous preparations (reviewed in Squillaro et al (68), Kouroupis et al (69)), to our knowledge there is no clinical studies reported on a comparison between different selected subpopulations. In this area, an unanswered question yet remains: do phenotypically-same subpopulations from different tissues behave similarly upon implantation, or the tissues of origin, rather than phenotypes, are more important?

## 2. MSC PRIMING

Efficacy and reproducibility of MSC therapies are not only affected by the composition of the cell preparation (above), but also by the capacity of the transplanted cells to consistently reach and interact with dysregulated tissues (*i.e.*, homing and engraftment) and subsequently to predictably induce and/or modify specific host responses (*i.e.*, therapeutic effect). In other words, after administration (*e.g.*, injection, infusion, etc.), MSCs have to migrate, home, engraft, survive, sense the local environment and reactively mount a paracrine reparative response. Previous studies have shown that systemically-infused MSCs (*e.g.*, intravenous or intra-arterial administration) are capable of migrating and homing to distant sites of active injury including BM, intestine, liver and lung (11, 70-72). However, only a small percentage of infused cells (*i.e.*, 0.1-2.7%) actually reaches the target tissues (73-78). Once at the injured tissue, it is well accepted that MSCs exert immunomodulatory (for both innate and adaptive immunity) and trophic activities (79, 80), recently suggested to be collectively called “medicinal” signaling activities (81, 82). These local activities are performed through both direct cell-cell communication (*e.g.*, Notch receptor /Jagged-1 and PD-1/PD-L1/PD-L2 (83, 84)) and locally secreted paracrine mediators. The latter involves a list of chemokines released by MSCs including C-X-C motif chemokine 12 (CXCL12) (85), stem cell factor (SCF) (86), platelet-derived growth factor (PDGF) (87), transforming growth factor  $\beta$  (TGF- $\beta$ ) (88), vascular endothelial growth factor (VEGF) (88), tumor necrosis factor- $\alpha$  stimulated gene/protein 6 (TSG-6) (89), erythropoietin (EPO) (88), interleukin-6 (IL-6) (88), interleukin-10 (IL-10) (88), indoleamine 2, 3-dioxygenase (IDO) (88) and prostaglandin E2 (PGE2) (90). Some of these factors (*e.g.*, TSG-6) have been shown to also exert a remote paracrine therapeutic effect, demonstrated in myocardial infarction (91), lung injury (92), and corneal injury (93),

suggesting that the induction of its secretion even without interaction with the target tissue might be sufficient for a therapeutic effect. On the other hand, host tissue conditions (*e.g.*, age and disease) also have an effect on the paracrine activity of engrafting MSCs (94-96). For instance, elevated levels of proteases such as elastase, cathepsin, and dipeptidylpeptidase (DPP) present in the aged tissue destabilize trophic factors induced by MSCs. Interestingly, the administration of a pharmacologic inhibitor of DPP prior the therapy enhanced the stability of CXCL12 and increased the engraftment and function of CXCR4<sup>+</sup> progenitor cells in an acute myocardial infarction mouse model (97). Collectively, this evidence suggests that both the “pharmacokinetic” properties and therapeutic activity of MSCs can be modulated and/or boosted a priori, through multiple *ex vivo* priming protocols. We now discuss a few techniques proposed to effectively prime MSCs before their transplantation *in vivo* (Figure 2).

### 2.1. Membrane and cytoplasmic MSC priming

MSCs express a variety of membrane adhesion molecules including intercellular adhesion molecules-1 and 2 (ICAM-1 and ICAM-2), vascular cell adhesion molecule-1 (VCAM-1), L-selectin, CD18, CD24, CD29, CD44, and CD49a-f (98, 99). Previous studies have shown that the adhesion molecule expression profile presents an intra-population heterogeneity (71), which is not only determined by the tissue of origin (100) but also by isolation and culture procedures. For instance, Aldridge et al., showed that early and late passaged MSCs have different adhesion molecule profiles, with CD49d exhibiting variable expression within the same cell population (71). Despite the potential deleterious effect this variability may have on cell adhesion processes, MSCs’ homing to target sites can be enhanced through diverse *in vitro* membrane modification techniques that incorporate natural and induced processes such as: a) the hematopoietic stem cell/leukocyte transendothelial migration process (*i.e.*, diapedesis); b) chemical or non-covalent interactions; and c) biospecific recognition. Early evidence has shown that engineering transmembrane glycoproteins on MSCs using characterized selectin ligands affects MSC migration through vasculature after systemic infusion *in vivo*, similar to leukocytes extravasation to inflamed tissues (101). Ruster et al. identified that MSCs, like leukocytes, roll and adhere to postcapillary venules via cellular interactions with ECs engaging P-

selectin as well as VCAM-1/(CD106) - VLA-4(CD49d/CD29) pathways (102, 103). As MSCs do not express P-selectin ligands such as glycoprotein ligand-1 (PSGL-1/CD162) or CD24, alternative ligands have been proposed (*e.g.*, CD44 glycoprotein which binds hyaluronic acid)(104).

Hematopoietic cell E-/L-selectin ligand (HCELL), a specific isoform of CD44 that binds strongly E-selectin (105), has been associated with MSC homing to BM *in vivo* (106) and thus its modification constitutes a promising approach to enhance that process. Using enzymatic conditions, Sackstein et al. (104) converted the MSC membrane native CD44 glycoprotein into HCELL allowing their efficient binding to E-selectin. The resulting sialofucosylated glycan moiety on CD44 is known as Sialyl-Lewis X (SLe<sup>x</sup>), the active selectin-binding carbohydrate motif site for HCELL. Interestingly, intravenously infused HCELL<sup>+</sup> MSCs infiltrated mouse BM within hours of infusion (104). Enzymatic membrane modification targets only glycoproteins that already exist on the surface of MSCs, whereas further chemical alterations enable the cells to present several epitopes via covalent bioconjugation method, potentially enhancing the effect. Importantly, Sarkar et al. used several approaches to covalently attach SLe<sup>x</sup> on MSC membrane through biotin-streptavidin binding, conferring leukocyte-like rolling characteristics to MSCs without affecting their phenotype and multilineage differentiation capacity (107, 108). These approaches resulted in increased MSC rolling on P-selectin at a physiological shear of 0.5 dyn/cm<sup>2</sup> *in vitro*. In an ear inflammation mouse model, SLe<sup>x</sup> engineered MSCs exhibited a robust rolling response on inflamed endothelium (109).

Another method to improve MSC homing is via antibody conjugation approach. To localize MSCs at a target tissue, researchers have used palmitated protein G or A pre-coating of the cell membrane as a step to bind antibodies on the MSC surface. Interestingly, Dennis et al. (110) have pre-coated the membrane of MSC chondrogenic progenitors with palmitated protein G and bound to the protein G antibodies specific for cartilage matrix antigens. Effective homing of membrane modified chondrogenic progenitors was observed to cartilage injury site in rabbit osteochondral explants (110). In another study, homing rate and repairing efficacy of MSCs improved using anti-CD29 and anti-myosin light chain bispecific antibodies in a mouse myocardial fibrosis model (111).



Importantly, in this study Deng et al. (111) also used highly focused ultrasound mediated stimulation of micro-bubbles, which significantly increases homing of MSCs to the mouse injured myocardium (112). Finally, another non-conventional method to enhance MSC homing is the internalization of superparamagnetic iron oxide nanoparticles with exogenously-guided magnetic targeting. This approach has been used by two separate studies showing enhanced MSC homing to mouse retina (113) and tail (114) and rabbit and swine osteochondral defects (115).

## 2.2. Cytokine and hormonal priming of cultured MSCs

An alternative approach to enhance homing and therapeutic capacity of MSCs is to prime the cells with specific cytokines and growth factors. Shi et al. showed that MSC priming with a cytokine cocktail containing SCF, HGF, IL-3 and IL-6 increases their CXCR4 expression (116). As a result, CXCR4 upregulation enhanced MSC chemotaxis to CXCL12 *in vitro* and homing efficiency to BM *in vivo*. Similarly, IL-1 $\beta$ -primed MSCs exhibited an enhanced homing capacity to inflammatory sites in an ulcerative colitis mouse model, also via upregulation of CXCR4 (117). Mechanistically, IL-1 $\beta$ -primed MSCs express multiple cytokines including TNF- $\alpha$ , IL-6, IL-8, IL23A, IL32 and chemokines CCL5, CCL20, CXCL1, CXCL3, CXCL5, CXCL6, CXCL10, CXCL11 and CX3CL1, as well as MMPs and adhesion molecules ICAM-1 and ICAM-4 (118). Interferon- $\gamma$  (IFN $\gamma$ ) is another molecule widely used to prime MSCs. It is a major pro-inflammatory mediator that has been shown to increase MSCs homing capacity to inflamed intestine in an ulcerative colitis mouse model, by upregulating CXCR7 and lectins LGALS3BP and LGALS9 in infused cells (119). A major effect of IFN $\gamma$  relies on the induction of the expression and activity in MSCs of the enzyme indoleamine 2,3-dioxygenase (IDO), involved in the direct suppression of T cells proliferation and activation (120, 121). IFN $\gamma$  priming also upregulates the production of IL-6 in MSCs (122), a cytokine with known anti-inflammatory and reparative effects *in vitro* and *in vivo* (e.g., liver fibrosis mouse model (123)). Therefore, due to its high potency in inducing immunomodulatory factors, IFN $\gamma$  has been proposed by many studies as a priming cytokine to enhance MSCs efficacy *in vivo*. Other priming methods with positive effects include exposure to complement component 1 subcomponent q (C1q), which enhances MSC homing by inducing chemotactic responses to SDF-1 gradient. Glycogen

synthase kinase 3 $\beta$  (GSK-3 $\beta$ ) inhibitors have also been used for MSC priming, resulting in increased MSC migration via the upregulation of  $\beta$ -catenin, phospho-c-Raf, ERK, phospho- $\beta$ -PAK-interacting exchange factor (124), enhancing CXCR4, MMP-1 and MMP-2 expression.

Hormonal priming of MSCs has been proposed as an additional method to improve MSC survival and to induce paracrine actions post-transplantation *in vivo* in various conditions such as myocardial infarction (125) and brain injury (126). Mias et al. also showed that MSCs primed with melatonin stimulated angiogenesis and proliferation of renal proximal tube cells *in vitro* via increased HGF and FGF-2 expression, and accelerated renal recovery *in vivo* following similar mechanisms and increased cell survival after transplantation (127). Melatonin MSC priming also showed beneficial effects in focal cerebral ischemia in rats, where it not only increased MSC survival post-transplantation *in vivo*, but also reduced brain infarction and increased angiogenesis and neurogenesis (126). On the other hand, oxytocin-primed MSCs reduced cardiac fibrosis and macrophage infiltration while enhanced cardiac repair for at least 4 weeks post-MSC transplantation *in vivo* (125). In a recent study, Liu et al. (128) showed that angiotensin-II hormone MSC priming results in reduced cardiac fibrosis and infarct size, improved cardiac function, increased expression of VEGF and von Willebrand factor in the ischemic myocardium but no MSC differentiation towards cardiomyocytes *in vivo*.

### 2.3. Hypoxia priming of cultured MSCs

Rapid loss of implanted MSCs *in vivo* has been associated with hypoxic stress at the ischemic target tissue, which can initiate cellular apoptosis (129). It is worth mentioning that MSCs are typically cultured at a pO<sub>2</sub> level of 142 mmHg (~20%), while the oxygen tension in the BM niche ranges from 1% to 7%, and in ischemic tissues from 0.4% to 2.3% (130). In a pioneering study, Annabi et al. identified that hypoxic environments (*i.e.*, 1% oxygen, 5% CO<sub>2</sub>, 94% nitrogen) induce *in vitro* MSC migration and three-dimensional capillary-like structure formation through the secretion of VEGF and MMP-1 (131). Moreover, this increased migratory behavior is explained by Akt signaling activation and induction of cMet expression, the main receptor of HGF (132), whereas the promotion of the MSC-dependent angiogenic effect is directly associated with the activation of hypoxia-

inducible factor-1 $\alpha$  (HIF-1 $\alpha$ )-78-kDa glucose-regulated protein (GRP78)-Akt signaling pathway (133). In general, MSC priming under hypoxia enhances the upregulation of several signaling molecules including CXCR4 (134-136), CX3CR1 (134), CXCL-12 (134, 135), VEGF (135) and vascular endothelial growth factor receptor-2 (VEGFR-2) (135), MMP-2 (136), MMP-9 (136), brain-derived neurotrophic factor (BDNF)(135), glial cell-derived neurotrophic factor (GDNF) (135), erythropoietin (EPO) (135) and its receptor EPOR (135), focal adhesion kinase (FAK) (137). The *in vivo* administration of hypoxia-primed MSCs show increased homing capacity, enhanced vascularization and restored function in various ischemic conditions, including myocardial infarction, cerebral and hind limb ischemia (132, 134-137). Mechanistically, two separate studies in mouse and rat myocardial infarction models showed that hypoxia-primed MSCs improve infarcted heart function via enhanced survival of implanted MSCs, increased angiogenesis and prevention of cardiomyocyte apoptosis through cell survival factor secretion (138, 139). These results were extended to diabetic cardiomyopathy, in which anoxia-primed MSCs improved cardiac function through not only anti-apoptotic effects but also attenuation of cardiac remodeling (140). In acute kidney injury, hypoxia-primed MSCs showed beneficial effects by improving renal function, increasing angiogenesis and reducing the levels of pro-inflammatory cytokines (141, 142).

Even though hypoxia-derived MSC priming has a positive influence on migration and homing capacities in several conditions, there is evidence of potential unwanted effects that require further investigation and that may indicate that hypoxia-priming may be application specific. This includes a negative effect on MSC osteogenic differentiation capacity (143), and the accumulation of reactive oxygen species (ROS) that alter their transcriptional factor profile (144). In contrast, Estrada et al. showed that low oxygen levels enhance cell proliferation and genetic stability by favoring a natural metabolic state of increased glycolysis and reduced oxidative phosphorylation (145). Therefore, further studies should carefully consider the long-term effects of hypoxia primed MSCs in models of disease.

#### **2.4. Induction of specific functional MSC phenotypes**

One of the main therapeutic mechanisms of MSCs at the target site is to immunomodulate local responses (80, 146). However, depending on the molecular composition of the instructive environment at the injury site, interacting MSCs exhibit a

therapeutic responsive polarization into either anti-inflammatory (MSC-2) or pro-inflammatory (MSC-1) phenotypes, tightly coupled to M2/M1 macrophage skewing (147, 148). Toll-like receptors (TLRs) are the most studied pattern recognition receptor family in MSCs, which sense pathogen-associated molecules involved in the regulation of innate immunity. Previous studies indicate that human MSCs consistently express TLR1, TLR2, TLR3, TLR4, TLR5, and TLR6, whereas TLR7, TLR8, TLR9, and TLR10 expression is dependent on the MSC origin (149-153). As elaborated below, several studies indicate that activation of specific TLRs in MSCs *in vitro* prior transplantation has a profound effect on the immunomodulatory capacities of MSCs. TLR3 and TLR4 are particularly important for MSCs' downstream effects, which can be *in vitro* activated by dsRNA mimetic polyinosinic-polycytidylic acid (*i.e.*, poly(I:C)) and lipopolysaccharide (LPS), respectively (147). Waterman et al. showed that TLR3 stimulation of MSCs supports their immunosuppressive effects preferentially through enhanced fibronectin deposition, whereas TLR4 stimulation of MSCs provides a more pro-inflammatory signature in part through release of TGF- $\beta$  and collagen deposition (147). In that respect, low-dose of poly(I:C) for 24h results in TLR3 activation and induction of VEGF, CXCL12, IL-6, IL-10, IL-11, leukemia inhibitory factor (LIF) and HGF without upregulation of inflammatory cytokines (154). Therefore, it is not surprising to observe that injection of poly(I:C)-treated MSCs in a hamster heart failure model, resulted in cardiac functional improvement with a 50% reduction in myocardial fibrosis, 40% reduction in apoptosis and 55% increase in angiogenesis (154). On the other hand, a recent study showed that both TLR3 and TLR4 activation comparably enhance MSC-mediated T regulatory cells (*i.e.*, Tregs) induction through Notch signaling and upregulation of Delta-like 1 (DL1), critical cellular mechanisms for the immunomodulatory properties of MSCs (155). In a rat acute myocardial infarction model, Yao et al. showed that LPS-dependent priming results in increased MSC survival post-transplantation *in vivo*, coupled with reduced fibrosis of the infarcted myocardium, increased neovascularization and earlier recovery of the cardiac function (156). Transcriptional profiling of LPS-primed MSCs showed that several chemokines, cytokines and adhesion molecules were highly up-regulated including *CXCL10*, *CCL20*, *IL8*, *CXCL1*, *IL6*, *CCL2*, *IL1B*, *CXCL2*, *IL1A*, *CXCL6*, *ICAM1*, *VCAM1*, and *SELE* (157).

Different studies have indicated contrasting effects of TLR activation on MSC multi-differentiation potential. In a comparative study performed by Raicevic et al., TLR activation of MSCs with post-natal and perinatal origin resulted in differential osteogenic potential depending on MSC tissue of origin (158). TLR2 and TLR4 activation in umbilical cord blood-derived MSCs promote chondrogenesis and osteogenesis with different intensities, whereas adipogenic differentiation is not altered by such TLR activation (159). MSCs harvested from the umbilical cord showed differential responses in terms of osteogenic potency, with TLR4 activation increasing and TLR3 activation decreasing it, respectively (160). On the contrary, both TLR3 and TLR4 downstream signaling promote BM-MSCs' osteogenic potency (161), through activation of Wnt3 $\alpha$  and Wnt5a signaling (TLR4) (162). Several groups have reported comparable increased osteogenic potency with activation of TLR2-, TLR3, TLR4- primed adipose tissue MSCs (ASCs) with unaffected adipogenesis (149, 163). A novel pattern recognition receptor, the triggering receptor expressed on myeloid cells (TREM), identified to regulate myeloid cells function *in vitro* (164), has been associated also with MSCs. Zhang et al. indicated that one of TREM family members, TREM-2, is expressed in MSCs and its knockdown reduces TLR2, TLR4, and TLR6 expression, impairing MSCs' multi-differentiation potential (165). Thus, we could speculate that TREM-2 ligands would induce TLR-specific responses in favor of cell differentiation.

## 2.5. Priming MSCs in 3D spheroid cultures

Adult MSCs possess a remarkable ability to coalesce and assemble in tri-dimensional (3D) structures, reminiscent of their innate aggregation as limb cell precursors in the mesenchymal condensation during early skeletogenesis. In that context, 3D organoid formation *in vitro* closely recapitulates the *in vivo* MSC niche by providing spatial cell organization with increased cell-cell interactions. As a matter of fact, MSCs cultured in 3D spheroid cultures show stable immuno-phenotypic profile, with a significant enhancement in survival (166), homing (167), stemness features (168, 169), differentiation potential (168, 169), angiogenic effect (166) and anti-inflammatory properties(170). For example, in a mouse model of hind limb ischemia, MSC transplantation as 3D spheroids improved their survival compared with 2D expanded MSCs, by suppressing a key apoptotic signaling molecule (Bax), while activating anti-apoptotic signaling (BCL-2) (166). These

positive effects can also be attributed to improved resistance to oxidative stress-induced apoptosis exerted by hypoxia-induced genes (*e.g.*, VEGF-A, HIF-1 $\alpha$  and MnSOD), elevated by the hypoxic conditions at the spheroid core (171, 172).

Additional benefits of 3D cultures account for the established reduction in size of individual MSCs (about 0.25 to 0.5 the volume of an average 2D cultured cell), which reduce cell entrapment in the lungs when systemically infused (170). MSCs stemness features are also improved in 3D MSC spheroid cultures, evidenced by: 1) higher expansion and colony-forming activities (169); 2) enhanced differentiation capacities (168, 173, 174); and 3) changes in the epigenetic status of genes indicative of a more pluripotent nature (*NANOG*, *SOX2*, *OCT4*) (168). As expected given the presence of a stimulating variable oxygen tension within the spheroids, angiogenic properties of MSCs are positively affected by 3D spheroid priming. This trophic enhancement is produced via upregulation of key angiogenic factors including VEGF, HGF, FGF-2, angiogenin (ANG), and angiopoietin 2 (ANGPT-2) (167, 172, 175). Murphy et al. showed that MSC spheroids embedded in fibrin gel secrete up to 100-fold more VEGF compare to dissociated MSCs in fibrin gel (176). Additionally, other groups have reported an increased homing capacity of MSC spheroids through a significant upregulation in the expression of the CXCL12 chemokine receptor CXCR4 (167, 169). Enhanced anti-inflammatory effects of 3D cultures have been reported by previous studies indicating that MSC spheroid highly express TGF- $\beta$ 1, IL-6, TSG-6, stanniocalcin (STC-1), and PGE-2 anti-inflammatory molecules (170, 177, 178). As mentioned earlier, MSCs acquire effective anti-inflammatory properties after being primed with pro-inflammatory cytokines. Interestingly, Bartosh et al. showed that MSC aggregation into 3D spheroids activates the expression of IL-1 in an autocrine secretion manner, thus initiating an “auto-priming” effect (170). Contrarily, Redondo-Castro et al. reported that the combination of IL-1 stimulation with spheroid priming resulted in significantly increased expression of IL1-Ra, VEGF and G-CSF molecules without anti-inflammatory effects on LPS-treated microglial cells in co-cultures (179). The discrepancies of the data underline the necessity for optimization of the priming methods and culture conditions. As a recent effort, Ylostalo et al. proposed specific protocols to efficiently

prime MSCs in 3-D cultures under chemically defined xeno-free conditions and how to administer the primed MSCs *in vivo* (180).

Finally, MSC-based 3D spheroids have been applied in various preclinical models including wound healing (171, 181), bone and osteochondral defects (182-184) and cardiovascular diseases (185, 186). Two separate groups applied MSC spheroids for wound healing in chemotherapy-induced oral mucositis (171) and in a model of diabetic healing impaired (leptin receptor-deficient mice) (181). In both cases MSC spheroid group provide better therapeutic efficacy compared with traditional MSC suspension group. Using a rat calvarial defect model, MSC spheroids implantation resulted in full-thickness bone formation that efficiently filled the generated bone defects (184). Intramyocardial transplantation of MSC spheroids in rat (185) and porcine (186) myocardial infarction models resulted in greater heart function improvement compared with MSC suspensions.

Collectively, MSC priming strategies aim to yield cellular products of high quality and potency by enhancing homing, survival, stemness, differentiation, anti-inflammatory and other MSC properties (Figures 2 and 3). As mentioned before, various methods exist to manipulate MSC properties that possess advantages and disadvantages mainly related to the quality of the cellular product (Table 7).

### 3. Clinical studies using functionalized MSCs

Up-to-date no clinical trials have been executed to evaluate the efficacy of MSC subpopulations. On the other hand, three clinical trials are currently registered in [www.clinicaltrials.gov](http://www.clinicaltrials.gov) using primed MSC. Despite the fact that various priming methods have been developed to enhance MSC properties *in vitro*, some with preclinical validation, the current clinical studies center on hypoxia/ischemia as the priming method to enhance MSC trophic properties. The phase 3 'STARTING-2' study (NCT01716481) evaluates the efficacy of intravenously infused autologous BM-derived MSCs pre-conditioned with autologous "ischemic serum" to treat stroke patients. A phase 1/2 study (NCT01849159) investigates the effectiveness of intravenously infused allogenic BM-derived MSCs primed *in vitro* under 1% hypoxia to regenerate the lungs of patients suffering from pulmonary emphysema. Finally, the 'TPAABPIHD' phase 1/2 study (NCT02504437) investigates

hypoxia-primed autologous BM-derived MSCs for their effectiveness to treat patients with ischemic heart diseases. Consequently, additional clinical research is needed to assess the safety and efficacy of “functional enhancing” strategies to MSC before administration, including cell selection and priming protocols.

#### **4. Conclusions**

It has become increasingly clear that current MSC culture-expansion methods, although proven to be clinically safe, do not guarantee the preservation of specific native MSC characteristics and attributes, thus yielding cell-based products of variable quality, and more importantly, potency. This in addition to inherent differences secondary to various factors including: origin of the cells (i.e., autologous or allogeneic), donor age and underlying pathological condition(s), and the recipient’s implantation site microenvironment. The resulting compromised standardization may account for the observed inconsistent therapeutic outcomes. Therefore, obtaining more homogeneous MSC preparations (e.g., through selection and/or induction by priming) in which the critical features are preserved may help circumvent the lack of reproducibility while enhancing their therapeutic effects (Figure 3). Thus, based on pre-clinical data, MSC subpopulation(s) selection and priming protocols may offer therapeutic advantages compared with the use of bulk/heterogeneous preparations in a number of clinical indications.

#### **ACKNOWLEDGMENTS**

We are in gratitude with the Soffer Family Foundation and the Diabetes Research Institute Foundation (DRIF) for their generous support. C. Sanjurjo-Rodriguez is beneficiary of a postdoctoral fellowship from Xunta de Galicia (Consellería de Cultura, Educación e Ordenación Universitaria).

#### **DISCLOSURE STATEMENT**

The authors declare no competing financial conflicts.



**ADDRESS CORRESPONDENCE TO:**

**Diego Correa, MD, MSc, PhD**

Department of Orthopedics – UHealth Sports Medicine Institute

Diabetes Research Institute & Cell Transplant Center,

University of Miami, Miller School of Medicine

1450 NW 10<sup>th</sup> Ave, Room 3014, Miami, FL, USA 33136.

Phone: +1 (305) 243-2228

Fax: +1 (305) 243-4404

Email: [dxc821@med.miami.edu](mailto:dxc821@med.miami.edu)

## REFERENCES

1. Wagner, W., Ho, A.D., and Zenke, M. Different Facets of Aging in Human Mesenchymal Stem Cells. *Tissue Engineering Part B-Reviews* **16**, 445, 2010.
2. Turinetto, V., Vitale, E., and Giachino, C. Senescence in Human Mesenchymal Stem Cells: Functional Changes and Implications in Stem Cell-Based Therapy. *International Journal of Molecular Sciences* **17**, E1164, 2016.
3. Sivasubramaniyan, K., Lehnen, D., Ghazanfari, R., Sobiesiak, M., Harichandan, A., Mortha, E., Petkova, N., Grimm, S., Cerabona, F., de Zwart, P., Abele, H., Aicher, W.K., Faul, C., Kanz, L., and Buhring, H.J. Phenotypic and functional heterogeneity of human bone marrow- and amnion-derived MSC subsets. *Annals of the New York Academy of Sciences* **1266**, 94, 2012.
4. Jones, E.A., Giannoudis, P.V., and Kouroupis, D. Bone repair with skeletal stem cells: rationale, progress to date and clinical application. *Therapeutic Advances in Musculoskeletal Disease* **8**, 57, 2016.
5. Bianco, P., and Robey, P.G. Skeletal stem cells. *Development* **142**, 1023, 2015.
6. Churchman S.M., Kouroupis D., Boxall S.A., Roshdy T., Tan H.B., McGonagle D., Giannoudis P.V., and Jones, E.A. Yield optimisation and molecular characterisation of uncultured CD271+ mesenchymal stem cells in the Reamer Irrigator Aspirator waste bag. *European Cells & Materials* **26**, 252, 2013.
7. Tormin, A., Li, O., Brune, J.C., Walsh, S., Schutz, B., Ehinger, M., Ditzel, N., Kassem, M., and Scheduling, S. CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. *Blood* **117**, 5067, 2011.
8. Espagnolle, N., Guilloton, F., Deschaseaux, F., Gadelorge, M., Sensebe, L., and Bourin, P. CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment. *Journal of Cellular and Molecular Medicine* **18**, 104, 2014.

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Tissue Engineering  
MSC functionalization for enhanced therapeutic applications (DOI: 10.1089/ten.TEB.2018.0118)

9. Maijenburg, M.W., Kleijer, M., Vermeul, K., Mul, E.P.J., van Alphen, F.P.J., van der Schoot, C.E., and Voermans, C. The composition of the mesenchymal stromal cell compartment in human bone marrow changes during development and aging. *Haematologica-the Hematology Journal* **97**, 179, 2012.
10. Boneberg, E.M., Illges, H., Legler, D.F., and Furstenberger, G. Soluble CD146 is generated by ectodomain shedding of membrane CD146 in a calcium-induced, matrix metalloprotease-dependent process. *Microvascular Research* **78**, 325, 2009.
11. Lin, P., Correa, D., Kean, T.J., Awadallah, A., Dennis, J.E., and Caplan, A.I. Serial Transplantation and Long-term Engraftment of Intra-arterially Delivered Clonally Derived Mesenchymal Stem Cells to Injured Bone Marrow. *Molecular Therapy* **22**, 160, 2014.
12. Somoza, R., Correa, D., and Caplan, A.I. Roles for mesenchymal stem cells as medicinal signaling cells **11**, 2016.
13. Mendelson, A., and Frenette, P.S. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. *Nature medicine* **20**, 833, 2014.
14. Méndez-Ferrer, S., Michurina, T.V., Ferraro, F., Mazloom, A.R., Macarthur, B.D., Lira, S.A., Scadden, D.T., Ma'ayan, A., Enikolopov, G.N., and Frenette, P.S. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature* **466**, 829, 2010.
15. Pinho, S., Lacombe, J., Hanoun, M., Mizoguchi, T., Bruns, I., Kunisaki, Y., and Frenette, P.S. PDGFR $\alpha$  and CD51 mark human Nestin(+) sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. *The Journal of Experimental Medicine* **210**, 1351, 2013.
16. Sacchetti, B., Funari, A., Michienzi, S., Di Cesare, S., Piersanti, S., Saggio, I., Tagliafico, E., Ferrari, S., Robey, P.G., Riminucci, M., and Bianco, P. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. *Cell* **131**, 324, 2007.

17. Corselli, M., Chin, C.J., Parekh, C., Sahaghian, A., Wang, W., Ge, S., Evseenko, D., Wang, X., Montelatici, E., Lazzari, L., Crooks, G.M., and Péault, B. Perivascular support of human hematopoietic stem/progenitor cells. *Blood* **121**, 2891, 2013.
18. Buhring, H.J., Battula, V.L., Trembl, S., Schewe, B., Kanz, L., and Vogel, W. Novel markers for the prospective isolation of human MSC. *Annals of the New York Academy of Sciences* **1106**, 262, 2007.
19. Battula, V.L., Trembl, S., Bareiss, P.M., Gieseke, F., Roelofs, H., de Zwart, P., Muller, I., Schewe, B., Skutella, T., Fibbe, W.E., Kanz, L., and Buhring, H.J. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. *Haematologica-the Hematology Journal* **94**, 173, 2009.
20. Busser, H., Najjar, M., Raicevic, G., Pieters, K., Pombo, R.V., Philippart, P., Meuleman, N., Bron, D., and Lagneaux, L. Isolation and Characterization of Human Mesenchymal Stromal Cell Subpopulations: Comparison of Bone Marrow and Adipose Tissue. *Stem Cells and Development* **24**, 2142, 2015.
21. Mabuchi, Y., Morikawa, S., Harada, S., Niibe, K., Suzuki, S., Renault-Mihara, F., Houlihan, D.D., Akazawa, C., Okano, H., and Matsuzaki, Y. LNGFR(+)THY-1(+)VCAM-1(hi+) Cells Reveal Functionally Distinct Subpopulations in Mesenchymal Stem Cells. *Stem Cell Reports* **1**, 152, 2013.
22. Li, H.Z., Ghazanfari, R., Zacharaki, D., Ditzel, N., Isern, J., Ekblom, M., Mendez-Ferrer, S., Kassem, M., and Scheduling, S. Low/Negative Expression of PDGFR-alpha Identifies the Candidate Primary Mesenchymal Stromal Cells in Adult Human Bone Marrow. *Stem Cell Reports* **3**, 965, 2014.
23. Sillaber, C., Walchshofer, S., Mosberger, I., Gaiger, A., Simonitsch, I., Chott, A., Lechner, K., and Valent, P. Immunophenotypic characterization of human bone marrow endosteal cells. *Tissue Antigens* **53**, 559, 1999.

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Tissue Engineering

MSC functionalization for enhanced therapeutic applications (DOI: 10.1089/ten.TEB.2018.0118)

Downloaded by Univ Of Western Ontario from www.liebertpub.com at 09/08/18. For personal use only.

24. Cuthbert, R.J., Giannoudis, P.V., Wang, X.N., Nicholson, L., Pawson, D., Lubenko, A., Tan, H.B., Dickinson, A., McGonagle, D., and Jones, E. Examining the Feasibility of Clinical Grade CD271(+) Enrichment of Mesenchymal Stromal Cells for Bone Regeneration. *Plos One* **10**, e011785, 2015.
25. Jezierska-Wozniak, K., Barczewska, M., Habich, A., Wojtacha, P., Badowska, W., Maksymowicz, W., and Wojtkiewicz, J. The feasibility of the CD271(+) and CD271(-) mesenchymal stromal cell enrichment toward nucleus pulposus-like cells. *Folia Histochemica Et Cytobiologica* **55**, 114, 2017.
26. Qian, H., Le Blanc, K., and Sigvardsson, M. Primary Mesenchymal Stem and Progenitor Cells from Bone Marrow Lack Expression of CD44 Protein. *Journal of Biological Chemistry* **287**, 25795, 2012.
27. Sousa, B.R., Parreira, R.C., Fonseca, E.A., Amaya, M.J., Tonelli, F.M.P., Lacerda, S., Lalwani, P., Santos, A.K., Gomes, K.N., Ulrich, H., Kihara, A.H., and Resende, R.R. Human Adult Stem Cells from Diverse Origins: An Overview from Multiparametric Immunophenotyping to Clinical Applications. *Cytometry Part A* **85A**, 43, 2014.
28. Lin, C.S., Ning, H.X., Lin, G.T., and Lue, T.F. Is CD34 truly a negative marker for mesenchymal stromal cells? *Cytotherapy* **14**, 1159, 2012.
29. Tormin, A., Brune, J.C., Olsson, E., Valcich, J., Neuman, U., Olofsson, T., Jacobsen, S.E., and Scheduling, S. Characterization of bone marrow-derived mesenchymal stromal cells (MSC) based on gene expression profiling of functionally defined MSC subsets. *Cytotherapy* **11**, 114, 2009.
30. Dickinson, S.C., Sutton, C.A., Brady, K., Salerno, A., Katopodi, T., Williams, R.L., West, C.C., Evseenko, D., Wu, L., Pang, S., de Godoy, R.F., Goodship, A.E., Peault, B., Blom, A.W., Kafienah, W., and Hollander, A.P. The Wnt5a Receptor, Receptor Tyrosine Kinase-Like Orphan Receptor 2, Is a Predictive Cell Surface Marker of Human Mesenchymal Stem Cells with an Enhanced Capacity for Chondrogenic Differentiation. *Stem Cells* **35**, 2280, 2017.

31. Freund, D., Fonseca, A.V., Janich, P., Bornhauser, M., and Corbeil, D. Differential expression of biofunctional GM1 and GM3 gangliosides within the plastic-adherent multipotent mesenchymal stromal cell population. *Cytotherapy* **12**, 131, 2010.
32. Jones, E., and Schafer, R. Biological Differences Between Native and Cultured Mesenchymal Stem Cells: Implications for Therapies. *Stem Cell Protocols* **1235**, 105, 2015.
33. Noort, W.A., Oerlemans, M.I.F.J., Rozemuller, H., Feyen, D., Jaksani, S., Stecher, D., Naaijken, B., Martens, A.C., Bühring, H.J., Doevendans, P.A., and Sluijter, J.P.G. Human versus porcine mesenchymal stromal cells: phenotype, differentiation potential, immunomodulation and cardiac improvement after transplantation. *Journal of Cellular and Molecular Medicine* **16**, 1827, 2012.
34. Mifune, Y., Matsumoto, T., Murasawa, S., Kawamoto, A., Kuroda, R., Shoji, T., Kuroda, T., Fukui, T., Kawakami, Y., Kurosaka, M., and Asahara, T. Therapeutic Superiority for Cartilage Repair by CD271-Positive Marrow Stromal Cell Transplantation. *Cell Transplantation* **22**, 1201, 2013.
35. Kuçi, S., Kuçi, Z., Kreyenberg, H., Deak, E., Pütsch, K., Huenecke, S., Amara, C., Koller, S., Rettinger, E., Grez, M., Koehl, U., Latifi-Pupovci, H., Henschler, R., Tonn, T., von Laer, D., Klingebiel, T., and Bader, P. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. *Haematologica* **95**, 651, 2010.
36. Mo, M., Wang, S., Zhou, Y., Li, H., and Wu, Y. Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential. *Cellular and Molecular Life Sciences* **73**, 3311, 2016.
37. Lv, F.-J., Tuan, R.S., Cheung, K.M.C., and Leung, V.Y.L. Concise Review: The Surface Markers and Identity of Human Mesenchymal Stem Cells. *Stem Cells* **32**, 1408, 2014.

38. Kocan, B., Maziarz, A., Tabarkiewicz, J., Ochiya, T., and Banaś-Ząbczyk, A. Trophic Activity and Phenotype of Adipose Tissue-Derived Mesenchymal Stem Cells as a Background of Their Regenerative Potential. *Stem Cells International* **2017**, 1653254, 2017.
39. Zimmerlin, L., Donnenber, V.S., Pfeifer, M.E., Meyer, E.M., Péault, B., Rubin, J.P., Donnenberg, A.D. Stromal Vascular Progenitors in Adult Human Adipose Tissue. *Cytometry Part A* **77A**, 406, 2010.
40. West, C.C., Hardy, W.R., Murray, I.R., James, A.W., Corselli, M., Pang, S., Black, C., Lobo, S.E., Sukhija, K., Liang, P., Lagishetty, V., Hay, D.C., March, K.L., Ting, K., Soo, C., and Peault, B. Prospective purification of perivascular presumptive mesenchymal stem cells from human adipose tissue: process optimization and cell population metrics across a large cohort of diverse demographics. *Stem Cell Research & Therapy* **7**, 47, 2016.
41. Bajek, A., Gurtowska, N., Gackowska, L., Kubiszewska, I., Bodnar, M., Marszalek, A., Januszewski, R., Michalkiewicz, J., and Drewa, T. Does the liposuction method influence the phenotypic characteristic of human adipose-derived stem cells? *Bioscience Reports* **35**, e00212, 2015.
42. Baer, P.C., Kuci, S., Krause, M., Kuci, Z., Zielen, S., Geiger, H., Bader, P., and Schubert, R. Comprehensive Phenotypic Characterization of Human Adipose-Derived Stromal/Stem Cells and Their Subsets by a High Throughput Technology. *Stem Cells and Development* **22**, 330, 2013.
43. Bourin, P., Bunnell, B.A., Casteilla, L., Dominici, M., Katz, A.J., March, K.L., Redl, H., Rubin, J.P., Yoshimura, K., and Gimble, J.M. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). *Cytotherapy* **15**, 641, 2013.
44. Lin, C.S., Xin, Z.C., Dai, J.C., and Lue, T.F. Commonly used mesenchymal stem cell markers and tracking labels: Limitations and challenges. *Histology and Histopathology* **28**, 1109, 2013.

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Tissue Engineering

MSC functionalization for enhanced therapeutic applications (DOI: 10.1089/ten.TEB.2018.01.18)

45. Sidney, L.E., Branch, M.J., Dunphy, S.E., Dua, H.S., and Hopkinson, A. Concise Review: Evidence for CD34 as a Common Marker for Diverse Progenitors. *Stem Cells* **32**, 1380, 2014.
46. Mitchell, J.B., McIntosh, K., Zvonic, S., Garretta, S., Floyd, Z.E., Kloster, A., Di Halvorsen, Y., Storms, R.W., Goh, B., Kilroy, G., Wu, X.Y., and Gimble, J.M. Immunophenotype of human adipose-derived cells: Temporal changes in stromal-associated and stem cell-associated markers. *Stem Cells* **24**, 376, 2006.
47. Szepesi, A., Matula, Z., Szigeti, A., Varady, G., Szalma, J., Szabo, G., Uher, F., Sarkadi, B., and Nemet, K. In Vitro Characterization of Human Mesenchymal Stem Cells Isolated from Different Tissues with a Potential to Promote Complex Bone Regeneration. *Stem Cells International* **3595941**, 2016.
48. Hardy, W.R., Moldovan, N.I., Moldovan, L., Livak, K.J., Datta, K., Goswami, C., Corselli, M., Traktuev, D.O., Murray, I.R., Peault, B., and March, K. Transcriptional Networks in Single Perivascular Cells Sorted from Human Adipose Tissue Reveal a Hierarchy of Mesenchymal Stem Cells. *Stem Cells* **35**, 1273, 2017.
49. Pak, J., Lee, J.H., Kartolo, W.A., and Lee, S.H. Cartilage Regeneration in Human with Adipose Tissue-Derived Stem Cells: Current Status in Clinical Implications. *Biomed Research International* **4702674**, 2016.
50. Chung, M.T., Liu, C., Hyun, J.S., Lo, D.D., Montoro, D.T., Hasegawa, M., Li, S., Sorkin, M., Rennert, R., Keeney, M., Yang, F., Quarto, N., Longaker, M.T., and Wan, D.C. CD90 (Thy-1)-Positive Selection Enhances Osteogenic Capacity of Human Adipose-Derived Stromal Cells. *Tissue Engineering Part A* **19**, 989, 2013.
51. Levi, B., Wan, D.C., Glotzbach, J.P., Hyun, J., Januszyk, M., Montoro, D., Sorkin, M., James, A.W., Nelson, E.R., Li, S., Quarto, N., Lee, M., Gurtner, G.C., and Longaker, M.T. CD105 Protein Depletion Enhances Human Adipose-derived Stromal Cell Osteogenesis through Reduction of Transforming Growth Factor  $\beta$ 1 (TGF- $\beta$ 1) Signaling. *The Journal of Biological Chemistry* **286**, 39497, 2011.



52. Johal, K.S., Lees, V.C., and Reid, A.J. Adipose-derived stem cells: selecting for translational success. *Regenerative medicine* **10**, 79, 2015.
53. Smith, M.D. The Normal Synovium. *The Open Rheumatology Journal* **5**, 100, 2011.
54. Roelofs, A.J., Zupan, J., Riemen, A.H.K., Kania, K., Ansboro, S., White, N., Clark, S.M., and De Bari, C. Joint morphogenetic cells in the adult mammalian synovium. *Nature Communications* **8**, 15040, 2017.
55. Decker, R.S., Um, H.-B., Dymont, N.A., Cottingham, N., Usami, Y., Enomoto-Iwamoto, M., Kronenberg, M.S., Maye, P., Rowe, D.W., Koyama, E., and Pacifici, M. Cell origin, volume and arrangement are drivers of articular cartilage formation, morphogenesis and response to injury in mouse limbs. *Developmental Biology* **426**, 56, 2017.
56. McGonagle, D., Baboolal, T.G., and Jones, E. Native joint-resident mesenchymal stem cells for cartilage repair in osteoarthritis. *Nature Reviews Rheumatology* **13**, 719, 2017.
57. McIntyre, J.A., Jones, I.A., Han, B., and Vangsness, C.T. Intra-articular Mesenchymal Stem Cell Therapy for the Human Joint: A Systematic Review. *The American Journal of Sports Medicine* **1**, 363546517735844, 2017.
58. Karystinou, A., Dell'Accio, F., Kurth, T.B.A., Wackerhage, H., Khan, I.M., Archer, C.W., Jones, E.A., Mitsiadis, T.A., and De Bari, C. Distinct mesenchymal progenitor cell subsets in the adult human synovium. *Rheumatology* **48**, 1057, 2009.
59. Jones, E.A., Kinsey, S.E., English, A., Jones, R.A., Straszynski, L., Meredith, D.M., Markham, A.F., Jack, A., Emery, P., McGonagle, D. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. *Arthritis and Rheumatism* **46**, 3349, 2002.
60. Van Landuyt, K.B., Jones, E.A., McGonagle, D., Luyten, F.P., and Lories, R.J. Flow cytometric characterization of freshly isolated and culture expanded human synovial cell populations in patients with chronic arthritis. *Arthritis Research & Therapy* **12**, R15, 2010.

61. Del Rey, M.J., Fare, R., Usategui, A., Canete, J.D., Bravo, B., Galindo, M., Criado, G., and Pablos, J.L. CD271(+) stromal cells expand in arthritic synovium and exhibit a proinflammatory phenotype. *Arthritis Research & Therapy* **18**, 66, 2016.
62. Hermida-Gomez, T., Fuentes-Boquete, I., Gimeno-Longas, M.J., Muinos-Lopez, E., Diaz-Prado, S., de Toro, F.J., and Blanco, F.J. Quantification of Cells Expressing Mesenchymal Stem Cell Markers in Healthy and Osteoarthritic Synovial Membranes. *The Journal of Rheumatology* **38**, 339, 2011.
63. Jones, E., Churchman, S.M., English, A., Buch, M.H., Horner, E.A., Burgoyne, C.H., Reece, R., Kinsey, S., Emery, P., McGonagle, D., and Ponchel, F. Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level. *Annals of the Rheumatic Diseases* **69**, 450, 2010.
64. Arufe, M.C., De la Fuente, A., Fuentes-Boquete, I., De Toro, F.J., and Blanco, F.J. Differentiation of Synovial CD-105(+) Human Mesenchymal Stem Cells Into Chondrocyte-Like Cells Through Spheroid Formation. *Journal of Cellular Biochemistry* **108**, 145, 2009.
65. Mizuno, M., Katano, H., Mabuchi, Y., Ogata, Y., Ichinose, S., Fujii, S., Otabe, K., Komori, K., Ozeki, N., Koga, H., Tsuji, K., Akazawa, C., Muneta, T., and Sekiya, I. Specific markers and properties of synovial mesenchymal stem cells in the surface, stromal, and perivascular regions. *Stem Cell Research & Therapy* **9**, 123, 2018.
66. Arufe, M.C., De la Fuente, A., Fuentes, I., de Toro, F.J., and Blanco, F.J. Chondrogenic potential of subpopulations of cells expressing mesenchymal stem cell markers derived from human synovial membranes. *Journal of Cellular Biochemistry* **111**, 834, 2010.
67. Gullo, F., and De Bari, C. Prospective purification of a subpopulation of human synovial mesenchymal stem cells with enhanced chondro-osteogenic potency. *Rheumatology* **52**, 1758, 2013.
68. Squillaro, T., Peluso, G., and Galderisi, U. Clinical Trials with Mesenchymal Stem Cells: An Update. *Cell Transplantation* **25**, 829, 2016.

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Tissue Engineering

MSC functionalization for enhanced therapeutic applications (DOI: 10.1089/ten.TEB.2018.01.18)

69. Kouroupis, D., Wang, X.N., El-Sherbiny, Y., McGonagle, D., and Jones, E. The Safety of Non-Expanded Multipotential Stromal Cell Therapies. In: Pham P.V., Rosemann A., eds. Safety, Ethics and Regulations. Cham: Springer International Publishing; 2017. pp. 91.
70. Chang, P., Qu, Y., Liu, Y., Cui, S., Zhu, D., Wang, H., and Jin, X. Multi-therapeutic effects of human adipose-derived mesenchymal stem cells on radiation-induced intestinal injury. *Cell Death & Disease* **4**, e685, 2013.
71. Aldridge, V., Garg, A., Davies, N., Bartlett, D.C., Youster, J., Beard, H., Kavanagh, D.P., Kalia, N., Frampton, J., Lalor, P.F., and Newsome, P.N. Human mesenchymal stem cells are recruited to injured liver in a  $\beta$ 1-integrin and CD44 dependent manner. *Hepatology* **56**, 1063, 2012.
72. Ortiz, L.A., Gambelli, F., McBride, C., Gaupp, D., Baddoo, M., Kaminski, N., and Phinney, D.G. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. *Proceedings of the National Academy of Sciences* **100**, 8407, 2003.
73. Devine, S.M., Cobbs, C., Jennings, M., Bartholomew, A., and Hoffman, R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. *Blood* **101**, 2999, 2003.
74. Gleeson, B.M., Martin, K., Ali, M.T., Kumar, A.H.S., Pillai, M.G.-K., Kumar, S.P.G., O'Sullivan, J.F., Whelan, D., Stocca, A., Khider, W., Barry, F.P., O'Brien, T., and Caplice, N.M. Bone Marrow-Derived Mesenchymal Stem Cells Have Innate Procoagulant Activity and Cause Microvascular Obstruction Following Intracoronary Delivery: Amelioration by Antithrombin Therapy. *Stem Cells* **33**, 2726, 2015.
75. Karp, J.M., and Leng Teo, G.S. Mesenchymal Stem Cell Homing: The Devil Is in the Details. *Cell Stem Cell* **4**, 206, 2009.

76. Gao, J.Z., Dennis, J.E., Muzic, R.F., Lundberg, M., and Caplan, A.I. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. *Cells Tissues Organs* **169**, 12, 2001.
77. Bentzon, J.F., Stenderup, K., Hansen, F.D., Schroder, H.D., Abdallah, B.M., Jensen, T.G., and Kassem, M. Tissue distribution and engraftment of human mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene. *Biochemical and Biophysical Research Communications* **330**, 633, 2005.
78. Kang, S.K., Shin, I.S., Ko, M.S., Jo, J.Y., and Ra, J.C. Journey of Mesenchymal Stem Cells for Homing: Strategies to Enhance Efficacy and Safety of Stem Cell Therapy. *Stem Cells International* **2012**, 11, 2012.
79. Najar, M., Raicevic, G., Crompot, E., Fayyad-Kazan, H., Bron, D., Toungouz, M., and Lagneaux, L. The Immunomodulatory Potential of Mesenchymal Stromal Cells: A Story of a Regulatory Network. *Journal of Immunotherapy* **39**, 45, 2016.
80. Caplan, A.I., and Correa, D. The MSC: An Injury Drugstore. *Cell Stem Cell* **9**, 11, 2011.
81. Caplan, A.I. Mesenchymal Stem Cells: Time to Change the Name! *Stem Cells Translational Medicine* **6**, 1445, 2017.
82. Caplan, A.I. New MSC: MSCs as pericytes are Sentinels and gatekeepers. *Journal of Orthopaedic Research* **35**, 1151, 2017.
83. Liotta, F., Angeli, R., Cosmi, L., Fili, L., Manuelli, C., Frosali, F., Mazzinghi, B., Maggi, L., Pasini, A., Lisi, V., Santarasci, V., Consoloni, L., Angelotti, M.L., Romagnani, P., Parronchi, P., Krampera, M., Maggi, E., Romagnani, S., and Annunziato, F. Toll-Like Receptors 3 and 4 Are Expressed by Human Bone Marrow-Derived Mesenchymal Stem Cells and Can Inhibit Their T-Cell Modulatory Activity by Impairing Notch Signaling. *Stem Cells* **26**, 279, 2008.
84. Augello, A., Tasso, R., Negrini, S.M., Amateis, A., Indiveri, F., Cancedda, R., and Pennesi, G. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. *European Journal of Immunology* **35**, 1482, 2005.

85. Togel, F.E., and Westenfelder, C. Role of SDF-1 as a regulatory chemokine in renal regeneration after acute kidney injury. *Kidney International Supplements* **1**, 87, 2011.
86. Walenda, T., Bokermann, G., Ventura Ferreira, M.S., Piroth, D.M., Hieronymus, T., Neuss, S., Zenke, M., Ho, A.D., Müller, A.M., and Wagner, W. Synergistic effects of growth factors and mesenchymal stromal cells for expansion of hematopoietic stem and progenitor cells. *Experimental Hematology* **39**, 617, 2011.
87. Tokunaga, A., Oya, T., Ishii, Y., Motomura, H., Nakamura, C., Ishizawa, S., Fujimori, T., Nabeshima, Y.-i., Umezawa, A., Kanamori, M., Kimura, T., and Sasahara, M. PDGF Receptor  $\beta$  Is a Potent Regulator of Mesenchymal Stromal Cell Function. *Journal of Bone and Mineral Research* **23**, 1519, 2008.
88. Kyurkchiev, D., Bochev, I., Ivanova-Todorova, E., Mourdjeva, M., Oreshkova, T., Belemezova, K., and Kyurkchiev, S. Secretion of immunoregulatory cytokines by mesenchymal stem cells. *World Journal of Stem Cells* **6**, 552, 2014.
89. Choi, H., Lee, R.H., Bazhanov, N., Oh, J.Y., and Prockop, D.J. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF- $\kappa$ B signaling in resident macrophages. *Blood* **118**, 330, 2011.
90. Hsu, W.-T., Lin, C.-H., Chiang, B.-L., Jui, H.-Y., Wu, K.K.-Y., and Lee, C.-M. Prostaglandin E2 Potentiates Mesenchymal Stem Cell-Induced IL-10+IFN- $\gamma$ +CD4+ Regulatory T Cells To Control Transplant Arteriosclerosis. *The Journal of Immunology* **190**, 2372, 2013.
91. Lee, R.H., Pulin, A.A., Seo, M.J., Kota, D.J., Ylostalo, J., Larson, B.L., Semprun-Prieto, L., Delafontaine, P., and Prockop, D.J. Intravenous hMSCs Improve Myocardial Infarction in Mice because Cells Embolized in Lung Are Activated to Secrete the Anti-inflammatory Protein TSG-6. *Cell Stem Cell* **5**, 54, 2009.
92. Danchuk, S., Ylostalo, J.H., Hossain, F., Sorge, R., Ramsey, A., Bonvillain, R.W., Lasky, J.A., Bunnell, B.A., Welsh, D.A., Prockop, D.J., and Sullivan, D.E. Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via

secretion of tumor necrosis factor- $\alpha$ -induced protein 6. *Stem Cell Research & Therapy* **2**, 27, 2011.

93. Roddy, G.W., Oh, J.Y., Lee, R.H., Bartosh, T.J., Ylostalo, J., Coble, K., Rosa, R.H., and Prockop, D.J. Action at a Distance: Systemically Administered Adult Stem/Progenitor Cells (MSCs) Reduce Inflammatory Damage to the Cornea Without Engraftment and Primarily by Secretion of TNF- $\alpha$  Stimulated Gene/Protein 6. *Stem Cells* **29**, 1572, 2011.

94. Lee, T. Host tissue response in stem cell therapy. *World Journal of Stem Cells* **2**, 61, 2010.

95. Dimmeler, S., and Leri, A. Aging and Disease as Modifiers of Efficacy of Cell Therapy. *Circulation Research* **102**, 1319, 2008.

96. Conboy, I.M., Conboy, M.J., Wagers, A.J., Girma, E.R., Weissman, I.L., and Rando, T.A. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. *Nature* **433**, 760, 2005.

97. Zaruba, M.-M., Theiss, H.D., Vallaster, M., Mehl, U., Brunner, S., David, R., Fischer, R., Krieg, L., Hirsch, E., Huber, B., Nathan, P., Israel, L., Imhof, A., Herbach, N., Assmann, G., Wanke, R., Mueller-Hoecker, J., Steinbeck, G., and Franz, W.-M. Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction. *Cell Stem Cell* **4**, 313, 2009.

98. Chamberlain, G., Fox, J., Ashton, B., and Middleton, J. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. *Stem Cells* **25**, 2739, 2007.

99. Majumdar, M.K., Keane-Moore, M., Buyaner, D., Hardy, W.B., Moorman, M.A., McIntosh, K.R., and Mosca, J.D. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. *Journal of Biomedical Science* **10**, 228, 2003.

100. De Ugarte, D.A., Alfonso, Z., Zuk, P.A., Elbarbary, A., Zhu, M., Ashjian, P., Benhaim, P., Hedrick, M.H., and Fraser, J.K. Differential expression of stem cell mobilization-associated

molecules on multi-lineage cells from adipose tissue and bone marrow. *Immunology Letters* **89**, 267, 2003.

101. Weber, C., Fraemohs, L., and Dejana, E. The role of junctional adhesion molecules in vascular inflammation. *Nature Reviews Immunology* **7**, 467, 2007.

102. Ruster, B., Göttig, S., Ludwig, R.J., Bistran, R., Müller, S., Seifried, E., Gille, J., and Henschler, R. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. *Blood* **108**, 3938, 2006.

103. Chigae, A., Wu, Y., Williams, D.B., Smagley, Y., and Sklar, L.A. Discovery of Very Late Antigen-4 (VLA-4,  $\alpha 4\beta 1$  Integrin) Allosteric Antagonists. *Journal of Biological Chemistry* **286**, 5455, 2011.

104. Sackstein, R., Merzaban, J.S., Cain, D.W., Dagia, N.M., Spencer, J.A., Lin, C.P., and Wohlgemuth, R. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. *Nature Medicine* **14**, 181, 2008.

105. Burdick, M.M., Henson, K.A., Delgadillo, L.F., Choi, Y.E., Goetz, D.J., Tees, D.F.J., and Benencia, F. Expression of E-selectin ligands on circulating tumor cells: cross-regulation with cancer stem cell regulatory pathways? *Frontiers in Oncology* **2**, 103, 2012.

106. Avigdor, A., Goichberg, P., Shivtiel, S., Dar, A., Peled, A., Samira, S., Kollet, O., Hershkoviz, R., Alon, R., Hardan, I., Ben-Hur, H., Naor, D., Nagler, A., and Lapidot, T. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. *Blood* **103**, 2981, 2004.

107. Sarkar, D., Vemula, P.K., Teo, G.S.L., Spelke, D., Karnik, R., Wee, L.Y., and Karp, J.M. Chemical Engineering of Mesenchymal Stem Cells to Induce a Cell Rolling Response. *Bioconjugate Chemistry* **19**, 2105, 2008.

108. Sarkar, D., Vemula, P.K., Zhao, W., Gupta, A., Karnik, R., and Karp, J.M. Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting. *Biomaterials* **31**, 5266, 2010.

109. Sarkar, D., Spencer, J.A., Phillips, J.A., Zhao, W., Schafer, S., Spelke, D.P., Mortensen, L.J., Ruiz, J.P., Vemula, P.K., Sridharan, R., Kumar, S., Karnik, R., Lin, C.P., and Karp, J.M. Engineered cell homing. *Blood* **118**, e184, 2011.
110. Dennis, J.E., Cohen, N., Goldberg, V.M., and Caplan, A.I. Targeted delivery of progenitor cells for cartilage repair. *Journal of Orthopaedic Research* **22**, 735, 2004.
111. Deng, W., Chen, Q.-W., Li, X.-S., Liu, H., Niu, S.-Q., Zhou, Y., Li, G.-Q., Ke, D.-Z., and Mo, X.-G. Bone marrow mesenchymal stromal cells with support of bispecific antibody and ultrasound-mediated microbubbles prevent myocardial fibrosis via the signal transducer and activators of transcription signaling pathway. *Cytotherapy* **13**, 431, 2011.
112. Ghanem, A., Steingen, C., Brenig, F., Funcke, F., Bai, Z.-Y., Hall, C., Chin, C.T., Nickenig, G., Bloch, W., and Tiemann, K. Focused ultrasound-induced stimulation of microbubbles augments site-targeted engraftment of mesenchymal stem cells after acute myocardial infarction. *Journal of Molecular and Cellular Cardiology* **47**, 411, 2009.
113. Yanai, A., Häfeli, U.O., Metcalfe, A.L., Soema, P., Addo, L., Gregory-Evans, C.Y., Po, K., Shan, X., Moritz, O.L., and Gregory-Evans, K. Focused Magnetic Stem Cell Targeting to the Retina Using Superparamagnetic Iron Oxide Nanoparticles. *Cell Transplantation* **21**, 1137, 2012.
114. Landázuri, N., Tong, S., Suo, J., Joseph, G., Weiss, D., Sutcliffe, D.J., Giddens, D.P., Bao, G., and Taylor, W.R. Magnetic Targeting of Human Mesenchymal Stem Cells with Internalized Superparamagnetic Iron Oxide Nanoparticles. *Small* **9**, 4017, 2013.
115. Kobayashi, T., Ochi, M., Yanada, S., Ishikawa, M., Adachi, N., Deie, M., and Arihiro, K. A Novel Cell Delivery System Using Magnetically Labeled Mesenchymal Stem Cells and an External Magnetic Device for Clinical Cartilage Repair. *Arthroscopy: The Journal of Arthroscopic & Related Surgery* **24**, 69, 2008.
116. Shi, M., Li, J., Liao, L., Chen, B., Li, B., Chen, L., Jia, H., and Zhao, R.C. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. *Haematologica* **92**, 897, 2007.



117. Fan, H., Zhao, G., Liu, L., Liu, F., Gong, W., Liu, X., Yang, L., Wang, J., and Hou, Y. Pre-treatment with IL-1 $\beta$  enhances the efficacy of MSC transplantation in DSS-induced colitis. *Cellular and Molecular Immunology* **9**, 473, 2012.
118. Carrero, R., Cerrada, I., Lledó, E., Dopazo, J., García-García, F., Rubio, M.-P., Trigueros, C., Dorronsoro, A., Ruiz-Sauri, A., Montero, J.A., and Sepúlveda, P. IL1 $\beta$  Induces Mesenchymal Stem Cells Migration and Leucocyte Chemotaxis Through NF- $\kappa$ B. *Stem Cell Reviews* **8**, 905, 2012.
119. Duijvestein, M., Wildenberg, M.E., Welling, M.M., Hennink, S., Molendijk, I., van Zuylen, V.L., Bosse, T., Vos, A.C.W., de Jonge-Muller, E.S.M., Roelofs, H., van der Weerd, L., Verspaget, H.W., Fibbe, W.E., te Velde, A.A., van den Brink, G.R., and Hommes, D.W. Pretreatment with Interferon- $\gamma$  Enhances the Therapeutic Activity of Mesenchymal Stromal Cells in Animal Models of Colitis. *Stem Cells* **29**, 1549, 2011.
120. English, K., Barry, F.P., Field-Corbett, C.P., and Mahon, B.P. IFN- $\gamma$  and TNF- $\alpha$  differentially regulate immunomodulation by murine mesenchymal stem cells. *Immunology Letters* **110**, 91, 2007.
121. Spaggiari, G.M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M.C., and Moretta, L. Mesenchymal stem cells inhibit natural killer–cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. *Blood* **111**, 1327, 2008.
122. Xu, G., Zhang, Y., Zhang, L., Roberts, A.I., and Shi, Y. C/EBP $\beta$  Mediates Synergistic Upregulation of Gene Expression by Interferon- $\gamma$  and Tumor Necrosis Factor- $\alpha$  in Bone Marrow-Derived Mesenchymal Stem Cells. *Stem Cells* **27**, 942, 2009.
123. Nasir, G.A., Mohsin, S., Khan, M., Shams, S., Ali, G., Khan, S.N., and Riazuddin, S. Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice. *Journal of Translational Medicine* **11**, 78, 2013.

124. Kim, Y.S., Noh, M.Y., Kim, J.Y., Yu, H.-J., Kim, K.S., Kim, S.H., and Koh, S.-H. Direct GSK-3 $\beta$  Inhibition Enhances Mesenchymal Stromal Cell Migration by Increasing Expression of Beta-PIX and CXCR4. *Molecular Neurobiology* **47**, 811, 2013.
125. Kim, Y.S., Ahn, Y., Kwon, J.S., Cho, Y.K., Jeong, M.H., Cho, J.G., Park, J.C., and Kang, J.C. Priming of Mesenchymal Stem Cells with Oxytocin Enhances the Cardiac Repair in Ischemia/Reperfusion Injury. *Cells Tissues Organs* **195**, 428, 2012.
126. Yaohui, T., Beibei, C., Falei, Y., Xiaosong, H., Xiaojie, L., Jixian, W., Yongting, W., and Guo-Yuan, Y. Melatonin Pretreatment Improves the Survival and Function of Transplanted Mesenchymal Stem Cells after Focal Cerebral Ischemia. *Cell Transplantation* **23**, 1279, 2014.
127. Mias, C., Trouche, E., Seguelas, M.-H., Calcagno, F., Dignat-George, F., Sabatier, F., Piercecchi-Marti, M.-D., Daniel, L., Bianchi, P., Calise, D., Bourin, P., Parini, A., and Cussac, D. Ex Vivo Pretreatment with Melatonin Improves Survival, Proangiogenic/Mitogenic Activity, and Efficiency of Mesenchymal Stem Cells Injected into Ischemic Kidney. *Stem Cells* **26**, 1749, 2009.
128. Liu, C., Fan, Y., Zhou, L., Zhu, H.-Y., Song, Y.-C., Hu, L., Wang, Y., and Li, Q.-P. Pretreatment of mesenchymal stem cells with angiotensin II enhances paracrine effects, angiogenesis, gap junction formation and therapeutic efficacy for myocardial infarction. *International Journal of Cardiology* **188**, 22, 2015.
129. Chavakis, E., Koyanagi, M., and Dimmeler, S. Enhancing the Outcome of Cell Therapy for Cardiac Repair. *Progress From Bench to Bedside and Back* **121**, 325, 2010.
130. Ceradini, D.J., Kulkarni, A.R., Callaghan, M.J., Tepper, O.M., Bastidas, N., Kleinman, M.E., Capla, J.M., Galiano, R.D., Levine, J.P., and Gurtner, G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. *Nature Medicine* **10**, 858, 2004.
131. Annabi, B., Lee, Y.-T., Turcotte, S., Naud, E., Desrosiers, R.R., Champagne, M., Eliopoulos, N., Galipeau, J., and Béliveau, R. Hypoxia Promotes Murine Bone-Marrow-Derived Stromal Cell Migration and Tube Formation. *Stem Cells* **21**, 337, 2003.

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Tissue Engineering

MSC functionalization for enhanced therapeutic applications (DOI: 10.1089/ten.TEB.2018.0118)

132. Rosová, I., Dao, M., Capoccia, B., Link, D., and Nolta, J.A. Hypoxic Preconditioning Results in Increased Motility and Improved Therapeutic Potential of Human Mesenchymal Stem Cells. *Stem Cells* **26**, 2173, 2008.
133. Lee, J., Yoon, Y., and Lee, S. Hypoxic Preconditioning Promotes the Bioactivities of Mesenchymal Stem Cells via the HIF-1 $\alpha$ -GRP78-Akt Axis. *International Journal of Molecular Sciences* **18**, 1320, 2017.
134. Hung, S.-C., Pochampally, R.R., Hsu, S.-C., Sanchez, C., Chen, S.-C., Spees, J., and Prockop, D.J. Short-Term Exposure of Multipotent Stromal Cells to Low Oxygen Increases Their Expression of CX3CR1 and CXCR4 and Their Engraftment In Vivo. *PLOS ONE* **2**, e416, 2007.
135. Wei, L., Fraser, J.L., Lu, Z.-Y., Hu, X., and Yu, S.P. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. *Neurobiology of Disease* **46**, 635, 2012.
136. Wei, N., Yu, S.P., Gu, X., Taylor, T.M., Song, D., Liu, X.-F., and Wei, L. Delayed Intranasal Delivery of Hypoxic-Preconditioned Bone Marrow Mesenchymal Stem Cells Enhanced Cell Homing and Therapeutic Benefits after Ischemic Stroke in Mice. *Cell Transplantation* **22**, 977, 2013.
137. Hu, X., Wei, L., Taylor, T.M., Wei, J., Zhou, X., Wang, J.-A., and Ping Yu, S. Hypoxic preconditioning enhances bone marrow mesenchymal stem cell migration via Kv2.1 channel and FAK activation. *American Journal of Physiology - Cell Physiology* **301**, C362, 2011.
138. Uemura, R., Xu, M., Ahmad, N., and Ashraf, M. Bone Marrow Stem Cells Prevent Left Ventricular Remodeling of Ischemic Heart Through Paracrine Signaling. *Circulation Research* **98**, 1414, 2006.
139. Hu, X., Yu, S.P., Fraser, J.L., Lu, Z., Ogle, M.E., Wang, J.-A., and Wei, L. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. *The Journal of Thoracic and Cardiovascular Surgery* **135**, 799, 2008.

140. Li, J.H., Zhang, N., and Wang, J.A. Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy. *Journal of Endocrinological Investigation* **31**, 103, 2008.
141. Zhang, W., Liu, L., Huo, Y., Yang, Y., and Wang, Y. Hypoxia-Pretreated Human MSCs Attenuate Acute Kidney Injury through Enhanced Angiogenic and Antioxidative Capacities. *BioMed Research International* **2014**, 10, 2014.
142. Overath, J.M., Gauer, S., Obermüller, N., Schubert, R., Schäfer, R., Geiger, H., and Baer, P.C. Short-term preconditioning enhances the therapeutic potential of adipose-derived stromal/stem cell-conditioned medium in cisplatin-induced acute kidney injury. *Experimental Cell Research* **342**, 175, 2016.
143. Pattappa, G., Thorpe, S.D., Jegard, N.C., Heywood, H.K., de Bruijn, J.D., and Lee, D.A. Continuous and Uninterrupted Oxygen Tension Influences the Colony Formation and Oxidative Metabolism of Human Mesenchymal Stem Cells. *Tissue Engineering Part C: Methods* **19**, 68, 2012.
144. Crowder, S.W., Horton, L.W., Lee, S.H., McClain, C.M., Hawkins, O.E., Palmer, A.M., Bae, H., Richmond, A., and Sung, H.-J. Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. *The FASEB Journal* **27**, 2788, 2013.
145. Estrada, J.C., Albo, C., Benguria, A., Dopazo, A., Lopez-Romero, P., Carrera-Quintanar, L., Roche, E., Clemente, E.P., Enriquez, J.A., Bernad, A., and Samper, E. Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis. *Cell Death & Differentiation* **19**, 743, 2012.
146. Singer, N.G., and Caplan, A.I. Mesenchymal Stem Cells: Mechanisms of Inflammation. *Annual Review of Pathology: Mechanisms of Disease* **6**, 457, 2011.
147. Waterman, R.S., Tomchuck, S.L., Henkle, S.L., and Betancourt, A.M. A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype. *PLOS ONE* **5**, e10088, 2010.

148. Bernardo, M.E., and Fibbe, W.E. Mesenchymal Stromal Cells: Sensors and Switchers of Inflammation. *Cell Stem Cell* **13**, 392, 2013.
149. Lombardo, E., DelaRosa, O., Mancheño-Corvo, P., Menta, R., Ramírez, C., and Büscher, D. Toll-like Receptor–Mediated Signaling in Human Adipose-Derived Stem Cells: Implications for Immunogenicity and Immunosuppressive Potential. *Tissue Engineering Part A* **15**, 1579, 2008.
150. Tomchuck, S.L., Zwezdaryk, K.J., Coffelt, S.B., Waterman, R.S., Danka, E.S., and Scandurro, A.B. Toll-Like Receptors on Human Mesenchymal Stem Cells Drive Their Migration and Immunomodulating Responses. *Stem Cells* **26**, 99, 2008.
151. Opitz, C.A., Litzenburger, U.M., Lutz, C., Lanz, T.V., Tritschler, I., Köppel, A., Tolosa, E., Hoberg, M., Anderl, J., Aicher, W.K., Weller, M., Wick, W., and Platten, M. Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon- $\beta$  and Protein Kinase R. *Stem Cells* **27**, 909, 2009.
152. Krampera, M., Sartoris, S., Liotta, F., Pasini, A., Angeli, R., Cosmi, L., Andreini, A., Mosna, F., Bonetti, B., Rebellato, E., Testi, M.G., Frosali, F., Pizzolo, G., Tridente, G., Maggi, E., Romagnani, S., and Annunziato, F. Immune Regulation by Mesenchymal Stem Cells Derived from Adult Spleen and Thymus. *Stem Cells and Development* **16**, 797, 2007.
153. Romieu-Mourez, R., François, M., Boivin, M.-N., Bouchentouf, M., Spaner, D.E., and Galipeau, J. Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype. *The Journal of Immunology* **182**, 7963, 2009.
154. Mastri, M., Shah, Z., McLaughlin, T., Greene, C.J., Baum, L., Suzuki, G., and Lee, T. Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency. *American Journal of Physiology - Cell Physiology* **303**, C1021, 2012.

155. Rashedi, I., Gómez-Aristizábal, A., Wang, X.-H., Viswanathan, S., and Keating, A. TLR3 or TLR4 Activation Enhances Mesenchymal Stromal Cell-Mediated Treg Induction via Notch Signaling. *Stem Cells* **35**, 265, 2017.
156. Yao, Y., Zhang, F., Wang, L., Zhang, G., Wang, Z., Chen, J., and Gao, X. Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction. *Journal of Biomedical Science* **16**, 74, 2009.
157. Guijarro-Muñoz, I., Compte, M., Álvarez-Cienfuegos, A., Álvarez-Vallina, L., and Sanz, L. Lipopolysaccharide Activates Toll-like Receptor 4 (TLR4)-mediated NF-κB Signaling Pathway and Proinflammatory Response in Human Pericytes. *Journal of Biological Chemistry* **289**, 2457, 2014.
158. Raicevic, G., Najar, M., Pieters, K., De Bruyn, C., Meuleman, N., Bron, D., Toungouz, M., and Lagneaux, L. Inflammation and Toll-Like Receptor Ligation Differentially Affect the Osteogenic Potential of Human Mesenchymal Stromal Cells Depending on Their Tissue Origin. *Tissue Engineering Part A* **18**, 1410, 2012.
159. Kim, H.-S., Shin, T.-H., Yang, S.-R., Seo, M.-S., Kim, D.-J., Kang, S.-K., Park, J.-H., and Kang, K.-S. Implication of NOD1 and NOD2 for the Differentiation of Multipotent Mesenchymal Stem Cells Derived from Human Umbilical Cord Blood. *PLOS ONE* **5**, e15369, 2010.
160. Zhang, L., Liu, D., Pu, D., Wang, Y., Li, L., He, Y., Li, Y., Li, L., Qiu, Z., Zhao, S., and Li, W. The role of Toll-like receptor 3 and 4 in regulating the function of mesenchymal stem cells isolated from umbilical cord. *International Journal of Molecular Medicine* **35**, 1003, 2015.
161. Qi, C., Xiaofeng, X., and Xiaoguang, W. Effects of Toll-Like Receptors 3 and 4 in the Osteogenesis of Stem Cells. *Stem Cells International* **2014**, 7, 2014.
162. He, X., Wang, H., Jin, T., Xu, Y., Mei, L., and Yang, J. TLR4 Activation Promotes Bone Marrow MSC Proliferation and Osteogenic Differentiation via Wnt3a and Wnt5a Signaling. *PLOS ONE* **11**, e0149876, 2016.

163. Cho, H.H., Shin, K.K., Kim, Y.J., Song, J.S., Kim, J.M., Bae, Y.C., Kim, C.D., and Jung, J.S. NF- $\kappa$ B activation stimulates osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue by increasing TAZ expression. *Journal of Cellular Physiology* **223**, 168, 2010.
164. Ford, J.W., and McVicar, D.W. TREM and TREM-like receptors in inflammation and disease. *Current Opinion in Immunology* **21**, 38, 2009.
165. Zhang, W.-Q., Huang, S.-H., Huang, X., Li, J.-H., Ye, P., Xu, J., Zheng, P.-Z., Shen, H.-Y., and Huang, J.-R. Regulation of human mesenchymal stem cell differentiation by TREM-2. *Human Immunology* **77**, 476, 2016.
166. Bhang, S.H., Lee, S., Shin, J.-Y., Lee, T.-J., and Kim, B.-S. Transplantation of Cord Blood Mesenchymal Stem Cells as Spheroids Enhances Vascularization. *Tissue Engineering Part A* **18**, 2138, 2012.
167. Potapova, I.A., Brink, P.R., Cohen, I.S., and Doronin, S.V. Culturing of human mesenchymal stem cells as three-dimensional aggregates induces functional expression of CXCR4 that regulates adhesion to endothelial cells. *The Journal of Biological Chemistry* **283**, 13100, 2008.
168. Guo, L., Zhou, Y., Wang, S., and Wu, Y. Epigenetic changes of mesenchymal stem cells in three-dimensional (3D) spheroids. *Journal of Cellular and Molecular Medicine* **18**, 2009, 2014.
169. Cheng, N.-C., Wang, S., and Young, T.-H. The influence of spheroid formation of human adipose-derived stem cells on chitosan films on stemness and differentiation capabilities. *Biomaterials* **33**, 1748, 2012.
170. Bartosh, T.J., Ylostalo, J.H., Mohammadipoor, A., Bazhanov, N., Coble, K., Claypool, K., Lee, R.H., Choi, H., and Prockop, D.J. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. *Proceedings of the National Academy of Sciences* **107**, 13724, 2010.

171. Zhang, Q., Nguyen, A.L., Shi, S., Hill, C., Wilder-Smith, P., Krasieva, T.B., and Le, A.D. Three-Dimensional Spheroid Culture of Human Gingiva-Derived Mesenchymal Stem Cells Enhances Mitigation of Chemotherapy-Induced Oral Mucositis. *Stem Cells and Development* **21**, 937, 2012.
172. Potapova, I.A., Gaudette, G.R., Brink, P.R., Robinson, R.B., Rosen, M.R., Cohen, I.S., and Doronin, S.V. Mesenchymal Stem Cells Support Migration, Extracellular Matrix Invasion, Proliferation, and Survival of Endothelial Cells In Vitro. *Stem Cells* **25**, 1761, 2007.
173. Cipriano, M., Freyer, N., Knöspel, F., Oliveira, N.G., Barcia, R., Cruz, P.E., Cruz, H., Castro, M., Santos, J.M., Zeilinger, K., and Miranda, J.P. Self-assembled 3D spheroids and hollow-fibre bioreactors improve MSC-derived hepatocyte-like cell maturation in vitro. *Archives of Toxicology* **91**, 1815, 2017.
174. Wang, W., Itaka, K., Ohba, S., Nishiyama, N., Chung, U.-i., Yamasaki, Y., and Kataoka, K. 3D spheroid culture system on micropatterned substrates for improved differentiation efficiency of multipotent mesenchymal stem cells. *Biomaterials* **30**, 2705, 2009.
175. Yeh, H.-Y., Liu, B.-H., Sieber, M., and Hsu, S.-h. Substrate-dependent gene regulation of self-assembled human MSC spheroids on chitosan membranes. *BMC Genomics* **15**, 10, 2014.
176. Murphy, K.C., Fang, S.Y., and Leach, J.K. Human Mesenchymal Stem Cell Spheroids in Fibrin Hydrogels Exhibit Improved Cell Survival and Potential for Bone Healing. *Cell and tissue research* **357**, 91, 2014.
177. Ylöstalo, J.H., Bartosh, T.J., Coble, K., and Prockop, D.J. Human mesenchymal stem/stromal cells (hMSCs) cultured as spheroids are self-activated to produce prostaglandin E2 (PGE2) that directs stimulated macrophages into an anti-inflammatory phenotype. *Stem cells* **30**, 2283, 2012.
178. Zimmermann, J.A., and McDevitt, T.C. Pre-conditioning mesenchymal stromal cell spheroids for immunomodulatory paracrine factor secretion. *Cytotherapy* **16**, 331, 2014.



179. Redondo Castro, E., Cunningham, C., Miller, J., Brown, H., M. Allan, S., and Pinteaux, E. Changes in the secretome of tri-dimensional spheroid-cultured human mesenchymal stem cells in vitro by interleukin-1 priming. *Stem Cell Research & Therapy* **9**, 11, 2018.
180. Ylostalo, J.H., Bazhanov, N., Mohammadipoor, A., and Bartosh, T.J. Production and Administration of Therapeutic Mesenchymal Stem/Stromal Cell (MSC) Spheroids Primed in 3-D Cultures Under Xeno-free Conditions. *JoVE*, e55126, 2017.
181. Amos, P.J., Kapur, S.K., Stapor, P.C., Shang, H., Bekiranov, S., Khurgel, M., Rodeheaver, G.T., Peirce, S.M., and Katz, A.J. Human Adipose-Derived Stromal Cells Accelerate Diabetic Wound Healing: Impact of Cell Formulation and Delivery. *Tissue Engineering Part A* **16**, 1595, 2009.
182. Ma, D., Zhong, C., Yao, H., Liu, Y., Chen, F., Li, J., Zhao, J., Mao, T., and Ren, L. Engineering Injectable Bone Using Bone Marrow Stromal Cell Aggregates. *Stem Cells and Development* **20**, 989, 2011.
183. Suzuki, S., Muneta, T., Tsuji, K., Ichinose, S., Makino, H., Umezawa, A., and Sekiya, I. Properties and usefulness of aggregates of synovial mesenchymal stem cells as a source for cartilage regeneration. *Arthritis Research & Therapy* **14**, R136, 2012.
184. Suenaga, H., Furukawa, K.S., Suzuki, Y., Takato, T., and Ushida, T. Bone regeneration in calvarial defects in a rat model by implantation of human bone marrow-derived mesenchymal stromal cell spheroids. *Journal of Materials Science Materials in Medicine* **26**, 254, 2015.
185. Wang, C.-C., Chen, C.-H., Hwang, S.-M., Lin, W.-W., Huang, C.-H., Lee, W.-Y., Chang, Y., and Sung, H.-W. Spherically Symmetric Mesenchymal Stromal Cell Bodies Inherent with Endogenous Extracellular Matrices for Cellular Cardiomyoplasty. *Stem Cells* **27**, 724, 2009.
186. Emmert, M.Y., Wolint, P., Wickboldt, N., Gemayel, G., Weber, B., Brokopp, C.E., Boni, A., Falk, V., Bosman, A., Jaconi, M.E., and Hoerstrup, S.P. Human stem cell-based three-dimensional microtissues for advanced cardiac cell therapies. *Biomaterials* **34**, 6339, 2013.

187. Xia, L., McDaniel, J.M., Yago, T., Doeden, A., and McEver, R.P. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. *Blood* **104**, 3091, 2004.
188. Hahn, J.-Y., Cho, H.-J., Kang, H.-J., Kim, T.-S., Kim, M.-H., Chung, J.-H., Bae, J.-W., Oh, B.-H., Park, Y.-B., and Kim, H.-S. Pre-Treatment of Mesenchymal Stem Cells With a Combination of Growth Factors Enhances Gap Junction Formation, Cytoprotective Effect on Cardiomyocytes, and Therapeutic Efficacy for Myocardial Infarction. *Journal of the American College of Cardiology* **51**, 933, 2008.
189. Cheng, W., Su, J., Hu, Y., Huang, Q., Shi, H., Wang, L., and Ren, J. Interleukin-25 primed mesenchymal stem cells achieve better therapeutic effects on dextran sulfate sodium-induced colitis via inhibiting Th17 immune response and inducing T regulatory cell phenotype. *American Journal of Translational Research* **9**, 4149, 2017.
190. Aktas, E., Chamberlain Connie, S., Saether Erin, E., Duenwald-Kuehl Sarah, E., Kondratko-Mittnacht, J., Stitgen, M., Lee Jae, S., Clements Anna, E., Murphy William, L., and Vanderby, R. Immune modulation with primed mesenchymal stem cells delivered via biodegradable scaffold to repair an Achilles tendon segmental defect. *Journal of Orthopaedic Research* **35**, 269, 2016.
191. Guess Adam, J., Daneault, B., Wang, R., Bradbury, H., La Perle Krista, M.D., Fitch, J., Hedrick Sheri, L., Hamelberg, E., Astbury, C., White, P., Overolt, K., Rangarajan, H., Abu-Arja, R., Devine Steven, M., Otsuru, S., Dominici, M., O'Donnell, L., and Horwitz Edwin, M. Safety Profile of Good Manufacturing Practice Manufactured Interferon  $\gamma$ -Primed Mesenchymal Stem/Stromal Cells for Clinical Trials. *Stem Cells Translational Medicine* **6**, 1868, 2017.
192. Kim, D.S., Jang, I.K., Lee, M.W., Ko, Y.J., Lee, D.-H., Lee, J.W., Sung, K.W., Koo, H.H., and Yoo, K.H. Enhanced Immunosuppressive Properties of Human Mesenchymal Stem Cells Primed by Interferon- $\gamma$ . *EBioMedicine* **28**, 261, 2018.

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Tissue Engineering

MSC functionalization for enhanced therapeutic applications (DOI: 10.1089/ten.TEB.2018.0118)

193. Tang, Y., Cai, B., Yuan, F., He, X., Lin, X., Wang, J., Wang, Y., and Yang, G.-Y. Melatonin Pretreatment Improves the Survival and Function of Transplanted Mesenchymal Stem Cells after Focal Cerebral Ischemia. *Cell Transplantation* **23**, 1279, 2014.
194. Liu, Y.-Y., Chiang, C.-H., Hung, S.-C., Chian, C.-F., Tsai, C.-L., Chen, W.-C., and Zhang, H. Hypoxia-preconditioned mesenchymal stem cells ameliorate ischemia/reperfusion-induced lung injury. *PLOS ONE* **12**, e0187637, 2017.
195. Kim, Y., Jin, H.J., Heo, J., Ju, H., Lee, H.-Y., Kim, S., Lee, S., Lim, J., Jeong, S.Y., Kwon, J., Kim, M., Choi, S.J., Oh, W., Yang, Y.S., Hwang, H.H., Yu, H.Y., Ryu, C.-M., Jeon, H.B., and Shin, D.-M. Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease. *Leukemia* 2018.
196. Waterman, R.S., Henkle, S.L., and Betancourt, A.M. Mesenchymal Stem Cell 1 (MSC1)-Based Therapy Attenuates Tumor Growth Whereas MSC2-Treatment Promotes Tumor Growth and Metastasis. *PLOS ONE* **7**, e45590, 2012.
197. Fuenzalida, P., Kurte, M., Fernández-O'ryan, C., Ibañez, C., Gauthier-Abeliuk, M., Vega-Letter, A.M., Gonzalez, P., Irrarrázabal, C., Quezada, N., Figueroa, F., and Carrión, F. Toll-like receptor 3 pre-conditioning increases the therapeutic efficacy of umbilical cord mesenchymal stromal cells in a dextran sulfate sodium–induced colitis model. *Cytotherapy* **18**, 630, 2016.
198. Qiu, Y., Guo, J., Mao, R., Chao, K., Chen, B.l., He, Y., Zeng, Z.r., Zhang, S.h., and Chen, M.h. TLR3 preconditioning enhances the therapeutic efficacy of umbilical cord mesenchymal stem cells in TNBS-induced colitis via the TLR3-Jagged-1-Notch-1 pathway. *Mucosal Immunology* **10**, 727, 2016.
199. Xu, Y., Shi, T., Xu, A., and Zhang, L. 3D spheroid culture enhances survival and therapeutic capacities of MSCs injected into ischemic kidney. *Journal of Cellular and Molecular Medicine* **20**, 1203, 2016.

200. Lee, J.H., Han, Y.-S., and Lee, S.H. Long-Duration Three-Dimensional Spheroid Culture Promotes Angiogenic Activities of Adipose-Derived Mesenchymal Stem Cells. *Biomolecules & Therapeutics* **24**, 260, 2016.

**Table 1.** Membrane and cytoplasmic MSC priming

PRIMING METHOD	REFERENCE	TYPE OF CELLS	TYPE OF PRIMING	PRECLINICAL MODEL	OUTCOME IN VIVO
Membrane priming	Xia L et al., 2004 (197)	Human umbilical cord blood CD34+ cells	Enzymatic functionalization with selectin-binding motifs	Non-obese diabetic/severe combined immune deficiency (NOD/SCID) mouse model	Systemically administered functionalized-CD34 <sup>+</sup> cells showed increased bone marrow homing
Membrane priming	Sackstein R et al., 2008 (106)	Human BM MSCs	Enzymatic conversion of native CD44 into haematopoietic cell E-/L-selectin ligand (HCELL)	Non-obese diabetic/severe combined immune deficiency (NOD/SCID) mouse model	Intravenously infused HCELL (+) MSCs infiltrated marrow within hours of infusion
Cytoplasmic priming	Kobayashi T et al., 2008 (117)	Human BM MSCs	MSCs labeled with internalized superparamagnetic iron oxide nanoparticles (SPIONs)	Rabbit and Swine osteochondral defect models	Local knee administration of SPIONs-labelled MSCs showed increased homing at the osteochondral defect sites

Membrane priming	Ghanem A et al., 2009 (114)	Human BM MSCs	Combination of BM MSCs with ultrasound mediated stimulation of micro-bubbles	Acute myocardial ischemia and reperfusion rat model	MSCs migrate across the myocardial endothelium whereas micro-bubbles stimulation improves MSC myocardial engraftment and allows locoregional targeting of post-ischemic myocardium
Membrane priming	Sarkar D et al., 2011 (111)	Human BM MSCs	Conjugation of the sialyl Lewis <sup>x</sup> (sLe <sup>x</sup> ) moiety to MSCs' surface through biotin-streptavidin	Ear inflammation BALB/C mouse model	Systemically administered SLe <sup>x</sup> engineered MSCs exhibited a robust rolling response on inflamed endothelium
Membrane priming	Deng W et al., 2011 (113)	Mouse BM MSCs	Combination of BM MSCs with anti-CD29/anti-myosin light chain bispecific antibodies and ultrasound	Isoproterenol-induced myocardial fibrosis mouse model	The homing rate to injured myocardium and repairing efficacy of systemically

			mediated stimulation of micro-bubbles		administered MSCs improved
Cytoplasmic priming	Yanai A et al., 2012 (115)	Rat BM MSCs	MSCs labeled with internalized superparamagnetic iron oxide nanoparticles (SPIONs)	Retinal degeneration rat model	Increased retina homing of SPIONs-labelled MSCs after both systemic and intravitreal infusions under magnetic field
Cytoplasmic priming	Landázuri N et al., 2013 (116)	Human BM MSCs	MSCs labeled with internalized superparamagnetic iron oxide nanoparticles (SPIONs)	Mouse model	Systemically administered SPIONs-labelled MSCs showed increased tail homing under magnetic field

**Table 2.** Cytokine MSC priming

PRIMING METHOD	REFERENCE	TYPE OF CELLS	TYPE OF PRIMING	PRECLINICAL MODEL	OUTCOME IN VIVO
Cytokine priming	Shi M et al., 2007 (118)	Human fetal BM MSCs	MSC priming with SCF, HGF, IL-3 and IL-6 cocktail	Sublethally irradiated non-obese diabetic/severe combined immune deficiency (NOD/SCID) mouse model	Short-term (24 hours) MSC priming with the cytokine cocktail resulted in up-regulation of CXCR4 and increased MSC homing to the BM post-intravenous infusion
Cytokine priming	Hahn JY et al., 2008 (198)	Rat BM MSCs	MSC priming with FGF-2, IGF-1 and BMP-2 cocktail	Myocardial infarction rat model	Local transplantation of cytokine primed MSCs resulted in enhanced gap junction formation, smaller infarct size and better cardiac function than untreated MSC group
Cytokine priming	Fan H et al., 2012 (119)	Human Umbilical cord	IL-1 $\beta$ -primed MSCs	Dextran sulfate sodium (DSS)-induced ulcerative	Intravenously infused IL-1 $\beta$ -primed MSCs modulated the



		MSCs		colitis mouse model	balance of immune cells in the spleen and the mesenteric lymph nodes (MLNs) and possessed an enhanced homing capacity to inflammatory gut site via upregulation of CXCR4
Cytokine priming	Duijvestein M et al., 2011 (121)	Human BM MSCs	Interferon- $\gamma$ (IFN- $\gamma$ )-primed MSCs	Dextran sodium sulfate (DSS)- and trinitrobenzene sulfonate (TNBS)-induced ulcerative colitis mouse model	Intraperitoneally infused IFN $\gamma$ -primed MSCs show upregulated CXCR7, LGALS3BP, LGALS9 expression and increased homing to the inflamed intestines
Cytokine priming	Nasir GA et al., 2013 (125)	Mouse BM MSCs	Hepatic microenvironment priming with IL-6 intraperitoneal injections combined with MSC transplantation	Carbon tetrachloride (CCl <sub>4</sub> ) fibrotic liver mouse model	<i>In vivo</i> hepatic microenvironment priming with IL-6 resulted in increased MSCs homing to fibrotic liver and reduced

					fibrosis and apoptosis post-local liver MSC transplantation
Cytokine priming	Cheng W et al., 2017 (199)	Rat BM MSCs	IL-25-primed MSCs	Dextran sodium sulfate (DSS)- induced ulcerative colitis rat model	Intravenously infused IL-25-primed MSCs exert improved therapeutic effects on the intestinal inflammation which may be related to the inhibition of Th17 immune response and induction of T regulatory cell phenotype
Cytokine priming	Aktas E et al., 2017 (200)	Rat BM MSCs	TNF-a primed MSCs	Achilles tendon segmental defect rat model	- TNF-a-primed MSCs reduced IL-12 production and the number of M1 macrophages, whereas increased the percent of M2 macrophages, and synthesis of the anti-inflammatory

					<p>factor IL-4</p> <p>- Concentration of type I procollagen in the healing tissue and failure stress of the tendon were increased 4 weeks post-injury</p>
Cytokine priming	Guess AJ et al., 2017 (201)	Human and Mouse BM MSCs	Interferon- $\gamma$ (IFN- $\gamma$ )-primed MSCs	Total body irradiated mouse model	Intravenously infused IFN $\gamma$ -primed MSCs supported hematopoietic reconstitution without evidence of organ toxicity or tumor formation
Cytokine priming	Kim DS et al., 2018 (202)	Human BM MSCs	Interferon- $\gamma$ (IFN- $\gamma$ )-primed MSCs	Graft-versus-host disease in an immune deficiency (NOD/SCID) mouse model	Intravenously infused IFN $\gamma$ -primed MSCs effectively decreased clinical symptoms and immune cell infiltration into the skin and small intestine of GVHD mice, improving their survival rate

**Table 3.** Hormonal MSC priming

PRIMING METHOD	REFERENCE	TYPE OF CELLS	TYPE OF PRIMING	PRECLINICAL MODEL	OUTCOME IN VIVO
Hormonal priming	Mias C et al., 2009 (129)	Rat BM MSCs	Melatonin priming	Acute kidney injury rat model	Intra-parenchymal injection of melatonin primed MSCs resulted in increased MSC survival, angiogenesis, proliferation of renal cells and accelerated renal recovery
Hormonal priming	Kim YS et al., 2012 (127)	Human UC MSCs	Oxytocin priming	Myocardial infarction rat model	Intramyocardial injection of oxytocin primed MSCs reduced cardiac fibrosis and macrophage infiltration and enhanced cardiac repair for at least 4 weeks post-MSC transplantation <i>in vivo</i>
Hormonal priming	Tang Y et al., 2014 (203)	Rat BM MSCs	Melatonin priming	Focal cerebral ischemia rat model	Melatonin primed MSCs were stereotactically injected into

					the striatum of the ipsilateral hemisphere. Melatonin MSC priming increased MSC survival <i>in vivo</i> , whereas melatonin primed MSCs reduced brain infarction, increased angiogenesis and neurogenesis.
Hormonal priming	Liu C et al., 2015 (131)	Rat BM MSCs	Angiotensin-II priming	Myocardial infarction rat model	Angiotensin-II hormone MSC priming results in reduced cardiac fibrosis and infarct size, improved cardiac function, increased expression of VEGF and von Willebrand factor in the ischemic myocardium but no MSC differentiation towards cardiomyocytes after intra-myocardial injection <i>in vivo</i>

**Table 4.** Hypoxia MSC priming

<b>PRIMING METHOD</b>	<b>REFERENCE</b>	<b>TYPE OF CELLS</b>	<b>TYPE OF PRIMING</b>	<b>PRECLINICAL MODEL</b>	<b>OUTCOME IN VIVO</b>
Anoxia priming	Uemura R et al., 2006 (142)	Mouse BM MSCs	Hypoxic gas mixture MSC priming	Myocardial infarction mouse model	Anoxia primed MSCs improved infarcted heart function via enhanced survival of implanted MSCs and prevent left ventricular remodeling of ischemic heart through MSC paracrine signaling
Hypoxia priming	Hung SC et al., 2007 (137)	Human BM MSCs	Hypoxic gas mixture MSC priming	Xenotypic grafting early chick embryo model	Hypoxia primed MSCs showed increased homing capacity into early chick embryos and generated a variety of cell types in host tissues
Hypoxia priming	Rosová I et al., 2008 (135)	Human BM MSCs	Hypoxic gas mixture MSC priming	Non obese diabetic/severe combined immune deficiency (NOD/SCID) hind limb ischemia mouse model	Intra-arterial injected hypoxia primed MSCs increased locally muscle revascularization

Hypoxia priming	Hu X et al., 2008 (143)	Mouse BM MSCs	Hypoxic gas mixture MSC priming	Myocardial infarction mouse model	Hypoxia primed MSCs improve infarcted heart function via enhanced survival of implanted MSCs and increased angiogenesis
Anoxia priming	Li JH et al., 2008 (144)	Rat BM MSCs	Hypoxic gas mixture MSC priming	Diabetic cardiomyopathy rat model	Anoxia primed MSCs improved cardiac function through anti-apoptotic effects and attenuation of cardiac remodeling
Hypoxia priming	Hu X et al., 2011 (140)	Mouse BM MSCs	Hypoxic gas mixture MSC priming	Myocardial infarction rat model	Intravenously injected hypoxia primed MSCs showed increased homing capacity to injured myocardium
Hypoxia priming	Wei L et al., 2012 (138)	Rat BM MSCs	Hypoxic gas mixture MSC priming	Transient cerebral ischemia rat model	Intravenously injected hypoxia primed MSCs showed increased homing to the brain and resulted in enhanced angiogenesis and neurogenesis

Hypoxia priming	Wei N et al., 2013 (139)	Rat BM MSCs	Hypoxic gas mixture MSC priming	Focal cortex ischemic stroke mouse model	Intranasal administration of hypoxia primed MSCs resulted in increased homing and neuroprotective effects to the ischemic brain region
Hypoxia priming	Zhang W et al., 2014 (145)	Human AT MSCs	Hypoxic gas mixture MSC priming	Acute renal ischemia/reperfusion injury rat model	Hypoxia primed MSCs attenuate renal injury through enhanced angiogenic and antioxidative capacities
Hypoxia priming	Overath JM et al., 2016 (146)	Mouse AT MSCs	Hypoxic gas mixture MSC priming	Cisplatin-induced acute kidney injury mouse model	Hypoxia primed MSCs results in improved renal function and reduced levels of pro-inflammatory cytokines
Hypoxia priming	Liu YY et al., 2017 (204)	Rat BM MSCs	Hypoxic gas mixture MSC priming	Ischemia-reperfusion lung injury rat model	Hypoxia primed MSCs migrate into extravascular lung tissue and attenuate I/R lung injury through anti-oxidant, anti-inflammatory and anti-apoptotic mechanisms



Hypoxia priming	Kim YH et al., 2018 (205)	Human UCB MSCs	Hypoxic gas mixture MSC priming	Graft-versus-host disease in an immune deficiency (NOD/SCID) mouse model	Intravenously injected hypoxia primed MSCs resulted in significant improved survival, less weight loss, and reduced histopathologic injuries in GVHD target organs
-----------------	---------------------------	----------------	---------------------------------	--	--

**Table 5.** TLRs MSC priming

PRIMING METHOD	REFERENCE	TYPE OF CELLS	TYPE OF PRIMING	PRECLINICAL MODEL	OUTCOME IN VIVO
TLRs priming	Yao Y et al., 2009 (160)	Mouse BM MSCs	Lipopolysaccharide priming	Myocardial infarction rat model	LPS MSC priming results in increased MSC survival post-transplantation <i>in vivo</i> and as a result reduced fibrosis of infarcted myocardium, neovascularization and recovery of the cardiac function
TLRs priming	Mastri M et al., 2012 (158)	Porcine BM MSCs	Polyinosinic-polycytidylic acid priming	Cardiomyopathy hamster model	Intramuscular injection of poly(I:C) primed MSCs resulted in cardiac functional improvement with a 50% reduction in myocardial fibrosis, 40% reduction in apoptosis and 55% increase in angiogenesis

TLRs priming	Waterman RS et al., 2012 (206)	Human BM MSCs	Lipopolysaccharide priming	Epithelial ovarian cancer mouse model	Intraperitoneal injection of LPS primed MSCs (MSC1 phenotype) attenuated tumor growth and metastasis
TLRs priming	Fuenzalida et al., 2016 (207)	Human UC MSCs	Polyinosinic-polycytidylic acid priming and Lipopolysaccharide priming	Dextran sodium sulfate (DSS)- induced ulcerative colitis mouse model	- Intraperitoneal injection of poly(I:C) primed MSCs ameliorated the clinical and histopathological severity of the disease - Intraperitoneal injection of LPS primed MSCs significantly increased clinical signs of disease, colon shortening and histological disease index
TLRs priming	Qui Y et al., 2017 (208)	Human UC MSCs	Polyinosinic-polycytidylic acid priming	Trinitrobenzene sulfonic acid-induced colitis mouse model	- Intraperitoneal injection of poly(I:C) primed MSCs decreased a wide range of inflammatory cytokines and increased systemic interleukin-10 (IL-10)

					levels in colonic tissues - Poly(I:C) primed MSCs also impaired T-helper type 1/17 (Th1/17) cell expansion and enhanced the suppressive effects of regulatory T cells
--	--	--	--	--	--

**Table 6.** 3D spheroid MSC priming

<b>PRIMING METHOD</b>	<b>REFERENCE</b>	<b>TYPE OF CELLS</b>	<b>TYPE OF PRIMING</b>	<b>PRECLINICAL MODEL</b>	<b>OUTCOME IN VIVO</b>
3D spheroid priming	Wang CC et al., 2009 (189)	Rat BM MSCs	Spheroid MSC culturing	Acute myocardial infarction rat model	Intramyocardial injection of MSC spheroids showed superior heart function than MSC suspensions by increasing vascular density
3D spheroid priming	Bartosh TJ et al., 2010 (174)	Human BM MSCs	Spheroid MSC culturing	Peritonitis mouse model and NOD/SCID mouse model	- Intraperitoneal injection of MSC spheroids was more effective than MSCs from adherent monolayer cultures in suppressing inflammatory responses Spheroid MSCs - Intravenously injected MSC spheroids show better trafficking through the lungs and homing to spleen, liver, kidney, and heart due to their smaller volume from adherent cultures

3D spheroid priming	Amos PJ et al., 2009 (185)	Human AT MSCs	Spheroid MSC culturing	Full-thickness diabetic mouse wound model	Transplantation of MSC spheroids to the diabetic wounds resulted in significant increase in the rate of wound closure compared to wounds treated with an equal number of MSCs delivered in suspension
3D spheroid priming	Ma D et al., 2011 (186)	Rabbit BM MSCs	Spheroid MSC culturing	Ectopic bone formation nude mouse model and Orthotopic bone formation mandible rabbit model	<ul style="list-style-type: none"> <li>- Subcutaneously injected MSC spheroids showed significantly larger and denser ectopic bone at the injection sites than the MSCs suspension group</li> <li>- MSC spheroids' orthotopic injection locally at the mandibular fracture gap results in increased bone healing</li> </ul>
3D spheroid priming	Bhang SH et al., 2012 (170)	Human umbilical cord blood MSCs	Spheroid MSC culturing	Hindlimb ischemia mouse model	Intramuscularly injected MSC spheroids showed better survival compared to 2D expanded MSCs

					by suppressing apoptotic signaling (Bax molecule) and activating anti-apoptotic signaling (BCL-2 molecule)
3D spheroid priming	Cheng NC et al., 2012 (173)	Human AT MSCs	Spheroid MSC culturing	Hindlimb ischemia mouse model	Intramuscularly injected MSC spheroids showed higher cellular retention
3D spheroid priming	Zhang Q et al., 2012 (175)	Human gingiva MSCs	Spheroid MSC culturing	Chemotherapy-induced oral mucositis mouse model	Intraperitoneal injected MSC spheroids possessed better therapeutic efficacy than their adherent cells in reversing body weight loss and promoting the regeneration of disrupted epithelial lining of the mucositis tongues
3D spheroid priming	Suzuki S et al., 2012 (187)	- Human synovial MSCs - Rabbit synovial MSCs	Spheroid MSC culturing	Full-thickness osteochondral defect rabbit model	- Transplantation of MSC spheroids at osteochondral defect sites resulted in their prompt adherence by surface tension,

					without any loss. - MSC spheroid transplantation at relatively low density achieved successful cartilage regeneration
3D spheroid priming	Suenaga H et al., 2015 (188)	Human BM MSCs	Spheroid MSC culturing	Calvarial bone defect rat model	Locally transplanted MSC spheroids resulted in significant bone remodeling
3D spheroid priming	Xu Y et al., 2016 (209)	Human AT MSCs	Spheroid MSC culturing	Ischemia/reperfusion-induced acute kidney injury rat model	Injection into the kidney cortex of MSC spheroids protected the kidney against apoptosis, reduced tissue damage, promoted vascularization and ameliorated renal function
3D spheroid priming	Lee JH et al., 2016 (210)	Human AT MSCs	Spheroid MSC culturing	Hindlimb ischemia mouse model	Intramuscularly injected MSC spheroids showed better proliferation than their adherent cells




**Table 7.** Advantages and disadvantages of different MSC priming methods

PRIMING METHOD	ADVANTAGES	DISADVANTAGES
<b>Cytokine and hormonal</b>	<ul style="list-style-type: none"> <li>• Increased survival, homing capacity and migratory behavior</li> <li>• Enhanced anti-inflammatory MSC phenotype</li> </ul>	<ul style="list-style-type: none"> <li>• Use of pro-inflammatory priming conditions <i>in vitro</i> that may affect the MHC class I and class II levels pre-implantation in <i>vivo</i></li> </ul>
<b>Hypoxia</b>	<ul style="list-style-type: none"> <li>• Increased homing capacity, migratory behavior and vascularization</li> </ul>	<ul style="list-style-type: none"> <li>• Accumulation of reactive oxygen species</li> <li>• Putative negative effect on MSC differentiation capacity</li> </ul>
<b>Immunomodulatory/functional</b>	<ul style="list-style-type: none"> <li>• Increased MSC polarization into anti-inflammatory (MSC-2) phenotype</li> <li>• Enhanced production of immunoregulatory molecules</li> <li>• Increased survival, homing and migratory capacities</li> </ul>	<ul style="list-style-type: none"> <li>• Toll-like receptors (TLRs) activation influence MSC differentiation capacities in an MSC tissue of origin-dependent manner</li> </ul>
<b>3D spheroid cultures</b>	<ul style="list-style-type: none"> <li>• Increased stability of MSC immunophenotypic profile</li> </ul>	<ul style="list-style-type: none"> <li>• Size variability for effective <i>in vivo</i> implantation</li> </ul>


	<ul style="list-style-type: none"><li>• Enhanced survival, homing, stemness features, differentiation potential, angiogenic effect and anti-inflammatory properties</li></ul>	<ul style="list-style-type: none"><li>• Depending on spheroid size, limited diffusion of nutrients and oxygen in 3D spheroid core</li><li>• Depending on spheroid size, necrotic spheroid core</li></ul>
--	---	--

## FIGURE LEGENDS:




**Figure 1:** MSC topography within bone marrow.

All BM MSCs are  $CD271^+$ , whereas  $CD146$  and  $CD56$  help discriminate their differential presence within two distinct anatomical regions of the BM: 1) the perivascular niche ( $CD146^+$ ) where they interact with blood vessels (arterioles and sinusoids), and 2) the bone-lining niche ( $CD146^{Neg}$   $CD56^+$ ) where they interact with cells of the osteoblastic lineage (quiescent bone lining cells and active osteoblasts in places of active remodeling).



**Figure 2:** MSC priming strategies include membrane modification, cytokine and hypoxia priming, Toll-like receptor priming, and 3D spheroid priming



**Figure 3:** MSC functionalization by priming in 2D and 3D cultures results in boosted homing, immunomodulatory and trophic effects *in vivo*.